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Abstract
Interstitial lung disease (ILD) and its associated treatments have the potential to put
patients at nutrition risk. However, minimal is known about the relationship between
nutritional status on disease severity and prognosis in ILD. Existing research is limited by
its focus on weight and body mass index (BMI). Therefore, the primary objective of this
cross-sectional, prospective study was to determine the prevalence of malnutrition using
the subjective global assessment (SGA) and to estimate body composition using
bioelectrical impedance analysis (BIA) among individuals with ILD (n = 78). A second
objective of this research was to investigate the appropriateness of bioimpedance
parameters such as standardized phase angle (SPhA) and impedance ratio z-score (z-IR)
as surrogate markers of malnutrition. The third objective of this research was to evaluate
how nutrition status and body composition are related to functional exercise capacity
using 6-minute walk distance (6MWD). The fourth objective explored the relationship
between fat-free mass index z-score (z-FFMI) and body fat mass index z-score (z-BFMI),
body composition measures which are controlled for age and sex, and nutrition status,
with survival. Results indicate that most participants were mildly malnourished (49%).
Additionally, 11.5% of patients had normal body composition, 20.5% were classified as
sarcopenic, 60% were obese and the remaining 8% were classified as sarcopenic obese.
z-FFMI and SGA were significantly associated with exercise capacity independent of
lung function. Low BMI, z-FFMI and z-BFMI were associated with severe malnutrition.
SPhA did not correlate with nutrition status, however, increased z-IR significantly
increased the odds of severe malnutrition. Age, BMI, z-FFMI, z-BFMI, exercise
capacity, disease severity, and severe malnutrition were significant predictors of survival.
z-FFMI and severe malnutrition were significantly associated with survival independent
of disease severity. These results are sufficiently encouraging to warrant further research
into the nutritional status of ILD patients. Future research should assess if nutrition
interventions can improve fat-free mass and functional exercise capacity in patients with
ILD. Assessment of fat-free mass should be considered alongside or in place of BMI as a
nutritional variable when analyzing survival risk in ILD patients as it can better identify
those as risk of death.
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Summary for Lay Audience
Interstitial lung disease (ILD) and its treatments put patients at risk of poor nutrition.
However, little is known about the link between nutrition and ILD, nor about the
influence of nutrition on survival in patients with ILD. Most ILD nutrition research has
focused on weight and body mass index (BMI). Therefore, the primary objective of this
study was to determine how common malnutrition is in ILD patients using the subjective
global assessment (SGA), and to estimate body composition (lean body mass and body
fat) using bioelectrical impedance analysis (BIA) among 78 individuals diagnosed with
ILD. A second objective of this research was to investigate if suspected markers of
nutrition status, such as, standardized phase angle (SPhA) and impedance ratio z-score (zIR) measured using BIA, can be used to accurately identify malnutrition. The third
objective of this research was to explore how nutrition status and body composition are
related to exercise capacity, using 6-minute walk distance (6MWD). Lastly, the fourth
objective explored the relationship between body composition and nutrition status with
survival. A large portion of the patients were mildly malnourished (49%). Lean body
mass controlled for age, sex and height, and nutrition status were significantly associated
with exercise capacity regardless of the severity of ILD. Low BMI, low muscle mass and
low body fat were associated with severe malnutrition. z-IR, but not SPhA, was
associated with severe malnutrition. Age, BMI, lean body mass, body fat, exercise
capacity, disease severity and severe malnutrition predicted survival in ILD patients.
Muscle mass controlled for age, sex and height, and severe malnutrition predicted
survival regardless of disease severity. These results justify future exploration into the
nutritional status of ILD patients which can be used to develop individualized nutrition
care plan for patients with ILD. Future research should assess if nutrition interventions
can increase muscle mass and/or exercise capacity. When possible, muscle mass should
be measured along with or in place of BMI as it can better identify those at risk of death
with ILD.
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Chapter 1
1

Introduction
Background

We take roughly 20,000 breaths each day, most of which we take no notice. However, for
most people it is not until breathing becomes a struggle, that it becomes obvious how
profound an impact the ability to breathe has on daily life. Interstitial lung disease (ILD)
comprises a heterogeneous range of chronic lung disorders which involve irritation and
swelling of the tissue lining the lungs making it difficult to breath (Bradley et al. 2008;
Cottin et al. 2019). ILD is associated with significant morbidity and mortality as survival
after diagnosis of some ILDs is only 2.5 to 5 years (Richeldi et al. 2003). The
management strategy of ILD includes home oxygen (Crockett, Cranston, and Antic
2001), pulmonary rehabilitation (Holland and Hill 2008; Nakazawa, Cox, and Holland
2017), and weight optimization (Alakhras et al. 2007). However, little is known about the
relationship between nutritional status and clinical course of ILD, a potentially important
implication on the outcome and quality of life of these patients.
Ample research indicates that ILD, its treatments and medication side-effects put patients
at nutrition risk (Quinn, Wisse, and Manns 2019; Trawinska, Rupesinghe, and Hart
2016). However, little is known about the relationship between nutritional status and
disease severity or prognosis in ILD patients. Existing research is limited by its focus on
weight and body mass index (BMI), and overlooks the components of body mass; fat-free
mass and body fat mass. Nutrition intervention can have a significant impact on clinical
outcomes such as improved quality of life and better tolerance to medical treatments
(Charney 2008). No nutrition recommendations are included in ILD best practice
guidelines (Raghu et al. 2015; Travis et al. 2013). Research using gold standard and wellaccepted clinical assessment tools is needed to determine the prevalence of malnutrition
and body composition concerns, such as inadequate fat-free mass, in ILD patients.
Addressing this research gap will help to establish best practice guidelines to be used by
clinicians to provide evidence-based and quality nutrition care to their ILD patients.
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At present, nutrition professionals such as registered dietitians (RDs) are not part of the
standard of care of ILD patients. For many, it is not until their disease has significantly
progressed that an RD may become involved in their care. For example, this may occur
due to a hospitalization or lung transplant assessment. For those individuals that require
lung transplantation assessment, this may be the first involvement of a RD in their care,
and the RD’s involvement is generally focused on weight management. As many ILD
patients are overweight or obese (Alakhras et al. 2007), therefore, weight loss may be
required to meet BMI cut-offs in order to receive a lung transplant. However, at this point
in their disease, many barriers, such as reduced exercise capacity (energy output) and
increase appetite secondary to medication use (energy input), make weight loss very
difficult to achieve. Additionally, due to disease exacerbations patients may end up in
hospital. Although, inpatient RD involvement can help address nutrition issues, that is if
the inpatient RD is referred to ILD patients in the first place, the hospital setting itself can
contribute to further malnutrition in these patients. Specifically, even just 1-week of bed
rest can lead to substantial loss of muscle mass and strength (Dirks et al. 2016) resulting
in patients leaving hospital deconditioned. Without adequate supports to address loss of
muscle mass post-hospital admission, this further contributes to the progressive loss of
functional capacity and risk of malnutrition in ILD patients.
Diminished exercise capacity in ILD is multifaceted with pathophysiological factors such
as impaired gas exchange in the lungs, altered respiratory mechanics, limited pulmonary
circulation and peripheral muscle dysfunction (Holland et al. 2008; Raghu et al. 2011). No
studies have explored the influence of poor nutrition status on diminished exercise capacity
in ILD. Clinical nutrition research is needed to determine if a relationship exists between
nutrition status and exercise capacity as this would provide justification for future research
into nutrition intervention as a non-exercise component in pulmonary rehabilitation
programs (Nakazawa, Cox, and Holland 2017).
The subjective global assessment (SGA) is the gold standard of nutrition assessment which
evaluates nutritional status subjectively. Phase angle (PhA), an indicator of cell health, is
obtained using bioelectrical impedance analysis (BIA) and is strictly an objective measure.
Unlike SGA, which requires a comprehensive assessment by a trained evaluator, PhA
2

measurement is a simple and non-invasive bedside technique. Research focused on the
utility of PhA as a surrogate marker of malnutrition has a low evidence quality (Rinaldi et
al. 2019). However, at present research is limited to only four disease states. The use of
PhA in nutrition assessment in disease has not been validated, therefore, more extensive
research in a variety of disease states, including ILD, is needed(Rinaldi et al. 2019)(Rinaldi
et al. 2019)(Rinaldi et al. 2019)(Rinaldi et al. 2019)(Rinaldi et al. 2019).
It has been suggested that increased BMI is correlated with an increased survival in ILD
(Alakhras et al. 2007). However, this reverse epidemiological effect of increased BMI fails
to recognize the important contribution of fat-free mass to health. ILD research has only
recently focused on fat-free mass as a promising predictor of survival (Nishiyama et al.
2017). Having identified fat-free mass as an important component of survival, it is pertinent
that research focused on how specific components of body weight, specifically fat-free
mass and body fat mass, influence survival in ILD continues. This area of research may
directly benefit ILD patients through improving the prognosis of their disease.

Research Purpose and Objectives of the Research
The overarching purpose of this dissertation research is to gain a better understanding of
nutritional concerns in ILD patients. Related to this purpose, this dissertation intends to
meet the following four research objectives.
1) The first objective of this research was to determine the prevalence of malnutrition using
the gold standard of nutrition assessment, subjective global assessment (SGA), and to
estimate body composition (fat-free mass index (FFMI) and body fat mass index (BFMI))
using BIA, among individuals with ILD.
2) The second objective of this research was to evaluate how nutrition status and body
composition are related to functional exercise capacity using 6-minute walk distance
(6MWD).
3) The third objective of this research was to investigate the utility of bioimpedance
parameters controlled for age, sex and/or BMI, such as 50 kHz PhA and 200/5 kHz
impedance ratio (IR) as surrogate markers of nutrition status in patients with ILD.
3

4) The fourth objective was to examine whether FFMI and BFMI controlled for age and
sex, and nutrition status were independent predictors of survival in ILD patients.

Study Area and Population
ILD typically affects middle-aged and older adults, with approximately two-thirds of
patients being 60 years and older at time of presentation of ILD (Kim 2006). The primary
population for this dissertation research was adults 18 years and older who were diagnosed
with ILD. Participants were recruited from one respiratory clinic taking place at London
Health Sciences Centre, Victoria Hospital in London, Ontario.

Outline of Dissertation
This dissertation is formatted in an integrated article approach. In the following chapters,
this dissertation addresses these four objectives. Following this introduction, Chapter 2
provides a literature review on background information relevant to these objectives
including disease background, nutrition-related knowledge to date in ILD including a
review of BIA and bioimpedance surrogate markers of nutrition status, nutrition-related
concerns with ILD medication use, and exercise capacity.
A literature review continues through Chapter 3 with a published review article on the
gold standard method of nutrition assessment, SGA, as well as, PhA, a measure of cell
health obtained using BIA. PhA is theorized to be an objective measure of nutrition status.
This published review assesses the literature on SGA and PhA, and critically reviews the
quality of evidence supporting PhA as a surrogate measure of nutrition status.
Chapter 4 specifically addresses the first three objectives of this dissertation; 1) to
determine prevalence of malnutrition and estimate body composition measures in ILD
patients, 2) to evaluate how nutrition status and body composition are related to functional
exercise capacity and 3) to determine the appropriateness of bioimpedance parameters to
identify malnutrition in ILD patients.

4

Chapter 5 addresses the fourth objective to examine whether nutrition status, and FFMI
and BFMI, controlled for age and sex, are independent predictors of survival in ILD
patients.
Lastly, Chapter 6 provides overall conclusions including the contributions to research,
clinical implications and recommendations, challenges and limitations of this thesis
research, and outlines plans and recommendations for future research directions.

5

Chapter 2
2

Literature Review – Part I
Nutrition-Related Concerns in Interstitial Lung Disease

This literature review is organized into two parts. This chapter concentrates on nutritionrelated concerns in interstitial lung disease (ILD). The second part of the literature review,
found in Chapter 3, is a published systematic review focused on assessing phase angle
(PhA) as a surrogate marker of nutrition using Subjective Global Assessment (SGA) as the
reference standard.
This chapter first provides a review of ILD etiology, prognosis and disease management
before turning to a review of the various nutrition-related concerns affecting ILD patients,
including body weight, body mass index (BMI), body composition concerns, nutritionrelated side effects associated with ILD medications, and functional exercise capacity as it
relates to nutrition status. Overviews of bioelectrical impedance analysis (BIA) and
bioimpedance surrogate markers of nutrition status which were used in this research are
also integrated in this section to provide appropriate background and context for the
discussed nutrition and ILD focused literature.

Interstitial Lung Disease
2.1.1

Etiology

Interstitial lung disease comprises a heterogeneous range of chronic lung disorders which
cause various degrees of inflammation or fibrosis in the pulmonary parenchyma including
the alveoli, trachea, bronchial tree, or blood vessels, and/or pleura (Bradley et al. 2008;
Cottin et al. 2019). One of the most common ILDs is idiopathic pulmonary fibrosis (IPF).
IPF is characterized by progressive fibrosis and architectural distortion of the lining of the
air sacs of the lungs, or alveoli, and is relentlessly progressive (Raghu et al. 2018). Other
fibrotic ILD subtypes include connective tissues disease-associated ILD, idiopathic
nonspecific interstitial pneumonias and chronic hypersensitivity pneumonitis (Ryerson et
al. 2016). While the etiology of some ILDs, including IPF, remains unknown (Travis et
al. 2013), others are caused by occupational, inorganic or organic exposures, drug-induced
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toxicities, or are secondary to CTD (Bradley et al. 2008). Reports of the incidence of ILD
subtypes is limited by the broad range of ILD and the rarity of some ILD subtypes (Olson
et al. 2018). In 2011, IPF affected 42 in 100,000 Canadians, of which the prevalence of IPF
was greater in males than females and drastically increased with advancing age (Hopkins
et al. 2016). As many ILDs are rare, recognizing and diagnosing specific subtypes require
considerable expertise.

2.1.2

Prognosis

The clinical course and outcome of ILD are highly variable between different subtypes
(Bradley et al. 2008), however, in general, ILD is associated with significant morbidity and
mortality (Richeldi et al. 2003). In IPF, survival after diagnosis is only 2.5 to 5 years in the
absence of treatment (Collard et al. 2003; Mura et al. 2012). Prognosis varies among and
within disease subtypes, and by a variety of clinical and demographic parameters.
Epidemiological data such as advancing age, male sex, and clinical features such as
symptoms of dyspnea are reliable predictors of survival at diagnosis of IPF (Fernández
Fabrellas et al. 2018). Clinical markers such as abnormal pulmonary function tests, 6minute walk distance (6MWD), dyspnea scores and BMI can help predict survival in ILD
(Alakhras et al. 2007; Collard et al. 2003; Manali et al. 2008). Specific clinical parameters
such as percent predicted diffusing capacity for carbon monoxide (%DLco) ≤ 40% at the
time of diagnosis, or a decline in %DLco or percent predicted forced vital capacity (%FVC)
overtime can predict survival in IPF (Fernández Fabrellas et al. 2018). A decline in %FVC
over time has been shown to be the best predictor of mortality, however, the minimum
clinically relevant change needed to predict mortality has varied (Fernández Fabrellas et
al. 2018). A one-time point measurement of %DLco, however, is considered the main
predictor of survival (Collard et al. 2003; Fernández Fabrellas et al. 2018; Hamada et al.
2007). For example, in a study of 78 IPF patients, %DLco, was the only significant predictor
of 5-year survival (r=0.557, p<0.0001) when controlled for age, sex, and cardiorespiratory
parameters (Hamada et al. 2007). Review of body mass, body composition and exercise
capacity as predictors of survival in ILD will be discussed in sections 2.2.1 and 2.2.2.2 of
this chapter.
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2.1.3

Disease Management

Medical therapeutic options vary among different types of ILD. Early identification,
aggressive treatment and lung transplantation remain the only recommendations for the
treatment of ILD (Travis et al. 2013). Treatments may include immunosuppressive therapy
(Richeldi et al. 2003; Spagnolo et al. 2010), anti-fibrotic or anti-inflammatory agents
(Hunninghake 2014; Richeldi et al. 2014), and, when medical therapy fails in eligible
patients, lung transplantation. Regardless of the etiology, the management strategy of ILD
includes supportive therapy such as home oxygen (Crockett, Cranston, and Antic 2001),
pulmonary rehabilitation (Holland and Hill 2008; Nakazawa, Cox, and Holland 2017), and
weight optimization (Alakhras et al. 2007). Guidance related to weight optimization in ILD
is limited and based on research related to body weight. Weight related research will be
discussed in the following sections.

Nutrition-Related Knowledge to Date
Little is known about the influence of nutritional status on the clinical course of ILD, a
potentially important implication on the outcome, functional capacity and quality of life of
these patients. Existing research is limited by its focus on weight and BMI as measures of
nutrition status. Therefore, current research does not fully address the influence of body
composition and overlooks the importance of a comprehensive nutrition assessment.

2.2.1

Body Mass

Body mass impacts the ability to breath, and thereby health status in ILD patients. Patients
with greater weight losses, especially lean body mass, have the greatest deterioration in
lung function (Tynan and Hasse 2004). Alternatively, obesity complicates breathing and
results in an increased workload and decreased functional exercise capacity (Tynan and
Hasse 2004). Therefore, in general, improving any patient’s nutritional status through
appropriate weight management should lead to an improved quality of life and improved
disease management.
Interestingly, multiple studies have found that increased BMI is correlated with an
increased survival rate in IPF patients (Alakhras et al. 2007; Mura et al. 2012). Alakhras et
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al. found that obesity (BMI >30 kg/m2) had a protective effect on morbidity of IPF patients
as compared to overweight (BMI 25-24.9 kg/m2) and normal weight (BMI <25 kg/m2)
patients. Mura et al. (2012) reported that for every 1-unit increase in BMI there was an
11% lower risk of death at 3-year follow-up (HR 0.89, p=0.0155). The concept of obesity
being protective suggests an inverse epidemiological effect, in that, increased weight may
offer protection against malnutrition and protect against potential harsh effects of medical
treatments (Alakhras et al. 2007). In support of this, progressive weight loss (greater than
5% of total body weight in 1 year) has also been found to be an independent predictor of
decreased survival in IPF (Nakatsuka et al. 2018). Although literature is largely focused
within IPF cases, one study, which included a diverse group of ILDs, including connective
tissues disease-associated ILD, chronic hypersensitivity pneumonitis, and unclassifiable
subtypes, found that a loss in BMI greater than 5% in 1 year was associated with
significantly shorter survival times, as well had a 2-fold higher risk of death compared to
those with a less than or equal to a 5% loss in BMI in 1 year (Pugashetti et al. 2018).
However, when assessed across ILD subtypes, the association between BMI decline and
survival was found to be significant in IPF and unclassifiable ILD, but not connective
tissues disease-associated ILD nor chronic hypersensitivity pneumonitis (Pugashetti et al.
2018). However, these results may have been limited by small sample size in the
connective tissues disease-associated ILD and chronic hypersensitivity pneumonitis
subtypes.
Collectively, these studies have not fully explored the influence of body mass across many
ILD subtypes, nor have they addressed the influence of fat-free mass or body fat mass on
survival. In other disease states, the obesity paradox, or the hypothesis that increased body
fat mass is protective only if fat-free mass is adequate, has been validated (Gonzalez et al.
2014). This suggests that BMI alone does not provide a complete picture of health.

2.2.2

Body Composition

Current research has failed to consider the impact of body composition as part of the
protective effect of increased BMI in ILD patients. A burgeoning area of research involves
the investigation of sarcopenia. Sarcopenia is a muscle disease defined by low muscle
quantity and strength, and in severe cases low physical performance (Cruz-Jentoft et al.
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2010). Presence of sarcopenia has been found to be associated with increased mortality,
infection, and hospital length of stay (Kyle et al. 2005). For the purpose of this dissertation,
sarcopenia and sarcopenic obesity have been identified using sex-specific cut-offs of
quantity of estimated fat-free mass index (FFMI) and body-fat mass index (BFMI) obtained
using BIA as outlined by Kyle et al. (2005). These cut-offs have been used by other groups
to identify sarcopenia and sarcopenic obesity (Gonzalez et al. 2014; Guida et al. 2019).
FFMI

and

𝐹𝐹𝑀𝐼 =

BFMI

are

calculated

𝑓𝑎𝑡−𝑓𝑟𝑒𝑒 𝑚𝑎𝑠𝑠 (𝐹𝐹𝑀) (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡 2 (𝑚2 )

according

and 𝐵𝐹𝑀𝐼 =

to

the

following

equations;

𝑏𝑜𝑑𝑦 𝑓𝑎𝑡 𝑚𝑎𝑠𝑠 (𝐵𝐹𝑀) (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡 2 (𝑚2 )

.

Low FFMI have been shown to be a predictor of mortality in various disease states such as
chronic obstructive pulmonary disease (COPD) (Schols et al. 2005) and liver cirrhosis
(Chang et al. 2019). Age, sex and height are main biological factors affecting fat-free mass,
but it may also be affected by environmental factors such as physical activity (Kyle et al.
2003). Nishiyama et al. (2017), were the first to demonstrate that FFMI, determined using
BIA, was a significant and independent predictor of survival in a cohort of Japanese IPF
patients. Specifically, a 36% lower risk of death with every 1 unit increase in FFMI (HR
0.64, 95% CI (0.43–0.94), p=0.02) was observed (Nishiyama et al. 2017). Conversely,
results from a conference abstract indicated no significant association between FFMI,
determined using BIA, and all-cause mortality at 1-year in IPF patients (Patel et al. 2018).
Of note, neither of these studies controlled for age or sex differences in their analyses of
FFMI. Therefore, one cannot distinguish whether it is disease-related and age-related
muscle loss that is associated with decreased survival.
The following subsections review BIA, its theoretical foundation, conditions and
contradictions for use, limitations, and comparison to alternative body composition
assessment methods.

2.2.2.1 Principles of Bioelectrical Impedance Analysis
BIA leverages the fact that body tissues vary in water and ionic (electrolyte) concentrations
and thus act as either conductors or insulators to an electrical current travelling through the
body. Muscle mass and body water, due to its large amounts of water and electrolytes, act
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as effective conductors. In other words, these body compartments offer less resistance to
an electrical current passing through them. Conversely, fat and bone mass are insulators as
the electrical current experiences more resistance due to the limited amount or lack of water
or ionic substances in these components. Therefore, body composition can be estimated
based on the underlying principle that the impedance of a cylindrical conductor with
uniform cross-sectional area (CSA) relates to its length, and specific resistivity (ρ) applied
at a fixed frequency, illustrated in Figure 1 (Kushner 1992).

cross-sectional area
𝑙𝑒𝑛𝑔𝑡ℎ
current
volume = cross-sectional area x length

1) 𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒 =

2) 𝑣𝑜𝑙𝑢𝑚𝑒 =

𝑟𝑒𝑠𝑖𝑠𝑡𝑖𝑣𝑖𝑡𝑦(𝑙𝑒𝑛𝑔𝑡ℎ)
⬚
cross-sectional
area

𝑟𝑒𝑠𝑖𝑠𝑡𝑖𝑣𝑖𝑡𝑦(𝑙𝑒𝑛𝑔𝑡ℎ)2
𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒

Figure 1 Cylindrical model of the relationship between the impedance of a current to the
specific resistivity (𝛒), length (L), cross-sectional area (CSA) and volume (V) of a
conductor.
We know that anatomically the body is not a single, symmetrical cylinder with uniform
cross-sectional area (Mulasi et al. 2015). Rather, BIA approximates the body as five
cylinders; one for each arm, one for each leg and one for the trunk. Therefore, these
components of the body collectively contribute to the total body impedance. Additionally,
the impedance of a conductor is a function of resistance and reactance according to the
following equation, 𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒 2 = 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 2 + 𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑐𝑒 2 (Kushner 1992). R is the
resistive effect exhibited on the current as it travels through water and electrolytes in fluid
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and tissues (Lukaski, Kyle, and Kondrup 2017). Reactance is related to the electrical charge
of the current through cells, tissues and non-ionic substances (Lukaski, Kyle, and Kondrup
2017). It is these raw bioimpedance measures that may be used in regression equations to
estimate various components of body composition such as muscle mass, body-fat or body
water. Generally, these equations are both age and sex specific, and are validated against
other methods of body composition assessment.

2.2.2.2 BIA Methods and Contraindications
BIA should be performed in ideal conditions to reduce measurement error. For instance,
participants should not exercise in the 24 hours prior to the completion of BIA testing.
Participants should abstain from eating or drinking within 4 hours of the test and should be
asked to empty their bladders just prior to the test to reduce inaccurate contributions of
consumed food or fluid in the BIA results (National Health Nutrition and Examination
Survery (NHANES) 2000). Electrodes through which the battery powered current flows
are placed on the surfaces of the hand and foot. See Appendix C for BIA testing protocol
including images on the proper placement of electrodes and body positioning. At the time
of the test, limb position should be controlled to prevent the limbs and trunk from touching
one another. Participants should be supine for 5-10 mins to help equalize body water in
order to account for potential fluid retention (Kyle, Genton, and Pichard 2013). In cases of
significant edema, results may be confounded. Therefore, clinical judgement may be
necessary to assess appropriateness of BIA in specific cases. In our cohort of ILD patients,
we did not note any patients with significant edema in our clinical assessments.
There are special cases where BIA is contraindicated. BIA is not recommended to be used
in pregnant or lactating women. BIA should not be completed on individuals with metal
implants as the presence of metal will interfere with the measurement of Z, R and Xc
producing inaccurate results. As well, individuals with pacemakers should not undergo
BIA measurement as the electrical current may interfere with their implanted device
causing harm to the participant (Kyle et al. 2004).
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2.2.2.3 Limitations
Measurement instruments have inherent limitations. Although the underlying principles of
BIA allow for body composition estimation, they also contain some inaccuracies. First, the
CSA of the body’s limbs and trunk are not of uniform area, nor perfectly symmetrical as
stated in the underlying principle of BIA. Secondly, it is assumed that current density
remains uniform across a conductor, however, the body is not homogeneous. Therefore,
current density will vary even when travelling through muscle, for example, due to
intramuscular fat. Additionally, body composition data obtained from BIA are predicted
values or estimations from regression equations developed for specific populations based
on age, sex and/or disease state. Generally, these regression equations are proprietary to
the manufacturer of the equipment, which is the case in the BIA device (BodyStat®
1500MD) used in this research. Therefore, one cannot say with absolute confidence that
these estimates are accurate in specific age ranges or disease. Regression equations based
on raw values of resistance and reactance are published for specific disease states, such as
COPD (de Blasio et al. 2017), however, there have been no regression equations published
within the ILD or IPF patient population. Although inherent limitations of the BIA
principles are not able to be controlled for, efforts should be made to minimize limitations
which can be controlled such as ensuring patients adhere to pre-testing guidelines, accurate
electrode and body positioning, and when possible patient specific regression equations
should be used.

2.2.2.4 Advantages and Comparison to Other Assessment
Techniques
Although BIA has notable limitations, it is important to acknowledge that BIA is a portable,
quick and non-invasive technique. It is a relatively inexpensive tool which can be used in
clinical practice to obtain a variety of detailed information related to body composition and
cell health. Other, more precise, measurement techniques such as the use of dual energy
X-ray absorptiometry scans, magnetic resonance imaging or computed tomography scans
measure body composition at the organ and tissue level (Prado, Birdsell, and Baracos
2009). However, major limitations to the use of dual energy X-ray absorptiometry,
magnetic resonance imaging and computed tomography imaging are their cost, availability
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and, most notably, radiation exposure to participants. Therefore, the ability to use the
techniques in research is generally limited, and when used these scans likely have been
previously completed for diagnostic or medical monitoring purposes which are typically
leveraged retrospectively for research purposes.

2.2.3

Malnutrition

Malnutrition has been defined as “a state resulting from lack of intake or uptake of nutrition
that leads to altered body composition (decreased fat-free mass) and body cell mass (total
cellular components of the body) leading to diminished physical and mental function and
impaired clinical outcome from disease” (Cederholm et al. 2015). Early identification of
malnutrition in chronic diseases is important in order to implement appropriate nutrition
care plans, thereby improving quality of life and tolerance to medical treatments (Charney
2008). Individuals at risk of malnutrition may be identified using nutrition screening tools
such as the Mini Nutrition Assessment®. Mini Nutrition Assessment® is a malnutrition
screening tool validated for older adults defined by age >65 years (See Appendix D)
(Bauer et al. 2008). Once identified as being at risk of malnutrition, individuals should
undergo in-depth nutrition assessment in order to identify nutritional deficiencies and
determine degree of malnutrition. The gold standard of nutrition assessment is the
subjective global assessment (SGA) developed by Detsky et al. 1987 (See Appendix B for
SGA scoring sheet) (Keith 2008). SGA combines dietary, weight, functional,
gastrointestinal and disease history with a physical examination to arrive at a categorical
ranking. SGA will be reviewed in further detail in Chapter 3 including its components and
various versions developed for specific patient populations.
To date, only a few nutrition screening tools, such as the Mini Nutrition Assessment® have
been used to assess risk of malnutrition in ILD/IPF patients, but no studies have used indepth nutrition assessments in ILD/IPF. An American study evaluated the nutrition status
of IPF patients using the Mini Nutrition Assessment®. Results from this study revealed
that approximately one quarter of participants were at risk of malnutrition while the
remaining were identified as normal nutritional status (Autore et al. 2013). Although, IPF
prevalence increases with age, authors concluded that the application of the Mini Nutrition
Assessment® in the general IPF population was not appropriate due to wide range of ages.
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Additionally, malnutrition prevalence in ILD has been estimated using single
anthropometric measures and varies greatly. For instance, a study of 81 IPF patients, of
which 88% were male, found that 28% of patients were malnourished using fat-free mass,
4% were malnourished using BMI, and 5% were malnourished using mid-arm
circumference (Jouneau et al. 2019). In ILD, the prevalence of malnutrition using
standardized and validated nutrition assessment tools is not well established.

2.2.3.1 Measurements of Nutritional Indicators
Trained clinicians, such as registered dietitians (RDs), needed to perform the SGA may
not be readily available as part of standard care, therefore surrogate markers of nutrition,
such as raw measures of BIA including PhA and impedance ratio (IR), have been
suggested in a number of different disease states (Kuchnia et al. 2017; Kyle et al. 2012;
Kyle, Genton, and Pichard 2013; Malecka-Massalska et al. 2016; Ott et al. 1995; Plank
and Li 2013). PhA will be discussed in further detail in Chapter 2.
IR and nutrition status are theorized to relate to each other through their common
association with alterations in body composition and body cell mass. IR is the ratio of
impedances at 200kHz and 5kHz obtained using BIA. As described in section 2.2.2.1.1.,
impedance includes two components; the resistance and reactance of a current as it passes
through the body. This research used multi-frequency BIA. multi-frequency BIA provides
the advantage of differentiating body water components; intracellular water and
extracellular water. Total body water is estimated when impedance is measured at high
frequencies (200kHz) which can pass through cell walls. However, impedance at low
frequencies (5kHz) have limited capacity to penetrate cell walls, therefore only
extracellular water is estimated. Therefore, IR =

impedance at 200kHz
impedance at 5kHz

=

total body water
extracellular water

(Rinninella et al. 2018). In healthy individuals, there is a large variation in impedances at
200kHz and 5kHz resulting in a lower value of IR. However, in malnutrition and disease,
cell walls can become damaged or weakened, allowing intracellular water to leak into the
extracellular space which may result in edema or third-spacing (Rinninella et al. 2018).
Therefore, the impedance at 5hHz, representing extracellular water, will approach that of
the total body water, and IR will near a value of 1. An IR closer to 1 is theorized to indicate
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poorer cellular health, abnormal hydration status and malnutrition (Kuchnia et al. 2017;
Lukaski, Kyle, and Kondrup 2017; Rinninella et al. 2018).
Although there has been growing interest in the use of raw bioimpedance parameters as
prognostic indicators and surrogate markers of nutrition status, no studies to date have
explored the relationship between PhA nor IR in ILD. As well, limited research exists on
the relationship between IR and nutrition status. Using total body protein as a measure of
nutrition status, Plank and Li (2013), demonstrated that a high IR, defined as >0.78 in males
and >0.82 in females, established from healthy volunteers, had significantly greater odds
of malnutrition [OR 4.15, CI 95% (1.77-9.75), p=0.001]. However, no studies have
compared IR with nutrition status assessed using nutrition screening tools, nor
comprehensive nutrition assessment methods such as SGA. Furthermore, the overall body
of research on IR and nutrition is lacking in its validation in clinical settings. Although IR
cut-offs have been suggested in other populations such as hospitalized inpatients (Plank
and Li 2013), in order to determine appropriate IR cut-off points population reference
norms are required. Recently, an American study using the National Health and Nutrition
Examination Survey 1999–2004 database published population reference values of PhA
and IR, therefore establishing cut-off points in a diverse American sample (Kuchnia et al.
2017). Further studies are needed to continue to validate IR as an accurate and appropriate
marker of nutrition status in health and disease.

2.2.4

Drugs and Nutrition

There is no cure for ILD aside from lung transplantation. Medical therapies are not curative,
rather they act to slow or stop disease progression (Trawinska, Rupesinghe, and Hart 2016).
In general, ILD/IPF medical therapies are used for either their anti-fibrotic, antiinflammatory or immune suppressing effects. However, these medications come with risks
of adverse events. Adverse events are the most common reason for patients to discontinue
medications (Trawinska, Rupesinghe, and Hart 2016). In general, medication-related
gastrointestinal (GI) adverse events can be managed through dose adjustment, treatment
interruption, and/or symptoms management (Quinn, Wisse, and Manns 2019). Therefore,
involvement of healthcare professionals to provide symptomatic and supportive care to
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patients in order to manage these medication-related adverse events is an important
component of ILD/IPF management.

2.2.4.1 Corticosteroids
Corticosteroids have anti-inflammatory properties which in early ILD management were
thought to be able to slow or stop the progression of fibrosis, respiratory failure and death
(Kim and Meyer 2008). Over the years, corticosteroids have not shown to be the most
effective therapy they were once expected to be. Therefore, previous clinical guidelines
have suggested, based on very-low quality evidence, that only a minority of patients with
acute exacerbations of their disease will experience a treatment benefit with corticosteroids
(Kim and Meyer 2008; Raghu et al. 2011). Nevertheless, corticosteroids, such as
prednisone, may be used in clinical practice. Common nutrition-related side effects,
depending on the dosage, include weight gain related to increased appetite or fluid retention
(US FDA approved prescribing information 1955). Several other ILD medications have
shown to be effective in the management of ILD which are discussed in the following
subsections.

2.2.4.2 Pirfenidone (Esbriet®)
Pirfenidone is an anti-fibrotic medication used in IPF patients and acts to suppress the
activity of fibrosis-associated pathways (Oku et al. 2008; Trawinska, Rupesinghe, and Hart
2016). Pirfenidone is also used for its antioxidant and anti-inflammatory effects (Somogyi
et al. 2019). A serious side-effect of pirfenidone includes photosensitivity. Patients are
instructed to limit their sun exposure and to use sun protective clothing and sun blocks
while on this medication (Kreuter 2014). Therefore, patients on pirfenidone have limited
vitamin D synthesis through the skin and must rely solely on diet and supplementation to
meet their vitamin D needs. Research has shown that ILD patients have a high incidence
of vitamin D deficiency (Hagaman et al. 2011), osteopenia and osteoporosis (Alhamad and
Nadama 2015). Other observed side effects with pirfenidone use are nausea, diarrhea,
vomiting, anorexia and dyspepsia/gastroesophageal reflux disease (Galli et al. 2017). In
clinical trials, the most common GI-associated adverse events were nausea and dyspepsia/
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gastroesophageal reflux disease which occurred in 36% and 18.5% of cases, respectively
(Galli et al. 2017).

2.2.4.3 Nintedanib (OFEV®)
Nintedanib is an anti-fibrotic medication used in IPF to slow the rate of lung function
decline (Galli et al. 2017; Trawinska, Rupesinghe, and Hart 2016). The most common GI
side effect experienced by patients is diarrhea. In clinical trials, 62% of patients
experienced diarrhea, 24.5% experienced nausea, 12% experienced vomiting and 11%
experienced anorexia (Galli et al. 2017). Additionally, over half of the adverse events
resulting in drug discontinuation were related to GI-associated adverse events (Galli et al.
2017).

2.2.4.4 N-acetylcysteine (NAC)
N-acetylcysteine (NAC) is an oral or inhaled antioxidant used in the treatment of IPF to
help prevent damage to the lungs (Trawinska, Rupesinghe, and Hart 2016). Common
adverse reactions can include nausea and vomiting, however, a double-blind, placebocontrolled trial showed no significant difference in adverse events in NAC versus placebo
(Martinez et al. 2014). Although it has been proven to be safe and well tolerated (Martinez
et al. 2014), current clinical practice guidelines, however, have stipulated a conditional
recommendation against its use due to non-significant changes in lung function nor
survival rates associated with its use (Raghu et al. 2015).

2.2.4.5 Mycophenolate Mofetil (CellCept®, Myfortic®)
Mycophenolate Mofetil (MMF) is a potent immunosuppressive and anti-inflammatory
medication typically used to prevent rejection after organ transplant. However, research
has suggested that MMF may also have an anti-fibrotic effect. Therefore, its use in certain
ILDs including connective tissues disease-associated ILD and chronic hypersensitivity
pneumonitis has grown. However, in IPF, only small, low-powered studies have been
published and provide mixed results (Nambiar, Anzueto, and Peters 2017). The most
common GI-associated adverse events include constipation, nausea, diarrhea, vomiting,
and dyspepsia (US FDA approved prescribing information 2015). Studies involving ILD
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patients have noted diarrhea to be the most frequent GI-associated symptom (Omair,
Alahmadi, and Johnson 2015). Despite its proposed anti-fibrotic effects, current clinical
practice guideline do not include recommendations for its use in IPF patients (Raghu et al.
2015).

2.2.4.6 Antacids
Antacids, such as, protein pump inhibitors for management of gastroesophageal reflux
disease are commonly prescribed in ILD patients to manage adverse effects resulting from
ILD/IPF medications. As well, there is a high incidence of gastroesophageal reflux disease
in IPF (Trawinska, Rupesinghe, and Hart 2016). This has led some to believe that
gastroesophageal reflux disease plays a role in the development and progression of IPF, or
many be an underlying cause of chronic cough in IPF (Raghu et al. 2006; Trawinska,
Rupesinghe, and Hart 2016).
It has been reported that prevalence of ILD increases with age (Olson et al. 2018).
Nutritional deficiencies associated with aging, confounded by nutrient-drug interactions
common in the ILD population puts ILD/IPF patients at higher risks of deficiencies. For
example, absorption of vitamin B12 first requires enough acid content in the stomach to be
able to release vitamin B12 from the protein it is attached to in food. However, with age
stomach acidity tends to decrease, and confounding this, protein pump inhibitors act to
reduce gastric acid secretion (McCaddon 2013). Therefore, especially in older patients with
IPF/ILD on protein pump inhibitors, absorptive capacity of vitamin B12 can be reduced
affecting patients’ serum blood levels leading to deficiency.
In summary, from a nutrition perspective, use of ILD medications puts patients at risk of
malnutrition whether it be through poor intake, decreased appetite, malabsorption, or any
combination of these. Therefore, specific and therapeutic nutritional support to manage
medication adverse events can help to prevent and/or correct malnutrition in ILD patients.
Therefore, it is important to be familiar with these medications and aware of their side
effects when assessing nutrition status of ILD patients.
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Exercise Capacity and Nutrition
Diminished exercise capacity is common among individuals with ILD (Mendes et al.
2015), which negatively contributes to their ability to participate in normal activities of
daily living, and thus compromises quality of life (Hansen and Wasserman 1996; Mendes
et al. 2015). Exercise capacity is measured using the six-minute walk test which is a routine
component in the standard care of ILD monitoring and management. The six-minute walk
test is a reliable and validated tool in ILD patients (Du Bois et al. 2011; Eaton et al. 2005;
Lederer et al. 2006; Serajeddini, Rogliani, and Mura 2018) which involves participants
walking as far and fast as they are able for 6 minutes. A change of 30 meters is generally
considered a clinically significant change in 6MWD in IPF patients (Fernández Fabrellas
et al. 2018; Nathan et al. 2015). Interestingly, six-minute walk test guidelines (American
Thoracic Society (ATS) 2002) suggest poor nutrition as a potential underlying cause of
low 6MWD and indicate that it should be further investigated.
Diminished exercise capacity in ILD is multifaceted with pathophysiological factors such
as impaired of gas exchange, altered respiratory mechanics, limited pulmonary circulation
and peripheral muscle dysfunction (Holland et al. 2008; Raghu et al. 2011). In other chronic
lung diseases, such as COPD, low 6MWD was associated with significantly greater odds
of poor nutrition status assessed using the Mini Nutrition Assessment® [OR 0.835 95% CI
(0.735-0.908), p=0.005] (Matkovic et al. 2017). Similarly, worsened nutrition status
assessed using Mini Nutrition Assessment® was associated with worse dyspnea score [OR
22.888, 95% CI (2.103-249.065), p=0.01], and lung function (FEV1/FVC ratio) [OR 0.898,
95% CI (0.826-0.977), p=0.012] in COPD patients (Mete et al. 2018).
In ILD, nutrition support is noted as a non-exercise component in pulmonary rehabilitation
programs (Nakazawa, Cox, and Holland 2017). However, specific nutrition
recommendations are not included in best practice guidelines (Raghu et al. 2015; Travis et
al. 2013). No studies have explored the influence of poor nutrition status on diminished
exercise capacity in ILD, therefore, research in this area is needed to better understand the
complex needs of this patient population.
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There are notable nutrition-related concerns associated with ILD and its management.
These concerns include maintaining a healthy body weight, optimizing body composition
and managing medication side-effects. In addition, poor nutrition status may be negatively
impact ILD patients’ functional level of exercise of everyday physical activities and thus
quality of life. Identifying and correcting malnutrition requires specialized skills and
assessment tools. Unfortunately, nutrition professions such as RDs needed to complete
these assessments may not be part of the health care team in standard ILD care. Therefore,
nutrition concerns in ILD patients may not be identified, nor appropriately managed. The
following chapter reviews the appropriateness and accuracy of PhA as an objective,
surrogate marker of nutrition status using SGA as the reference standard.
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Chapter 3
3

Literature Review – Part II
Is Phase Angle an Appropriate Indicator of Malnutrition
in Different Disease States? A Systematic Review

Publication citation: Rinaldi S, Gilliland J, O’Connor C, Chesworth B, Madill J. 2018.
“Is phase angle an appropriate indicator of malnutrition in different disease states? A
systematic review.” Clinical Nutrition European Society for Parenteral and Enteral
Nutrition 29: 1-14. doi:https://doi.org/10.1016/j.clnesp.2018.10.010.

Abstract
Background & aims: The subjective global assessment (SGA) classifies malnutrition
severity via a simple bedside assessment. Phase angle (PhA) is an indicator of cell
integrity and has been suggested to be indicator of nutritional status.
Objective: To explore the relationship between PhA and SGA.
Methods: Relevant studies published through October 31, 2017 were identified using 7
electronic databases. Articles were included for review if they included comparison data
between SGA and PhA within adult disease populations. Evidence quality was assessed
using the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE) guidelines and methodological quality was assessed using the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.
Results: 33 articles within four disease states (liver, hospitalization, oncology and renal)
met inclusion criteria for review. Results were limited by restricting the database search
to articles published in English only, and by the inherent difficulty of comparing 2
methods which are both influenced by the operator.
Conclusion: Based on GRADE guidelines, evidence quality received a grade of Low.
Based on QUADAS-2, 61% of studies had high risk of bias in the index test (PhA), while
all other domains had low risk. It is not possible to conclude that PhA is an accurate
independent indicator of malnutrition. PROSPERO no. CRD42016050876.
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Introduction
Malnutrition is a common concern in both chronic and acute disease with significant
implications on survival, quality of life, medical complications, and other socioeconomic
issues (McWhirter and Pennington 1994; K. Norman, Pichard, et al. 2008; Pirlich et al.
2005). There is a broad range of methods for nutrition assessment available to clinicians
(White et al. 2013). Subjective Global Assessment (SGA) is a nutritional assessment
method which classifies malnutrition severity via a bedside assessment (Detsky et al.
1987). It is the gold standard method to identify malnutrition (Keith 2008), and has been
validated in many disease states and clinical settings (Baccaro et al. 2007; Baker et al.
1982; Cooper et al. 2002; Correia and Waitzberg 2003; Jerin et al. 2003; Kondrup et al.
2003; Pirlich et al. 2005). SGA combines dietary, weight, functional, gastrointestinal and
disease history with a physical examination to arrive at a category ranking. SGA-A
represents a well-nourished state, SGA-B represents moderate malnutrition or suspected
of being malnourished and SGA-C represents severe malnutrition (Detsky et al. 1987).
Since its initial development, SGA has been adapted by various groups. Hasse et al., 1993
developed an adapted-SGA for liver disease, which accounts for additional clinical
conditions such as encephalopathy, infection, kidney function, and varices (Hasse et al.
1993). The CANADA-USA Peritoneal Dialysis Study Group developed a 7-point
modified SGA (7p-SGA) (Churchill, Taylor, and Keshaviah 1996). Kalantar-Zadeh and
colleagues, proposed a quantitative scoring system known as the quantitative-SGA
(QSGA), also referred to as Dialysis Malnutrition Score (Kalantar-Zadeh et al. 1999).
The Patient-Generated SGA (PG-SGA) combines a patient-generated component with a
professional assessment and is used most commonly in oncology and chronic catabolic
conditions (Bauer, Capra, and Ferguson 2002; Ottery 1996; Ottery and Jager-Wittenaar
2014).
Whereas SGA evaluates nutritional status subjectively, phase angle (PhA) is strictly an
objective measure. Unlike SGA which requires a comprehensive assessment by a trained
evaluator, PhA measurement is a simple, quick and non-invasive technique. PhA is a
measure of the resistance and reactance of a current as it passes through tissues of the
body via bioelectrical impedance analysis (BIA) (Barbosa-Silva and Barros 2005).
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Resistance is affected by the amount of fluid in the tissues of the body, whereas reactance
is affected by the type of body cells and their related permeability (Norman et al. 2015).
Age, sex, and BMI are the main biological factors affecting PhA (Norman et al. 2012).
PhA may also be affected by level of physical activity, fluid status, and body composition
(Norman et al. 2012; Tynan and Hasse 2004). The calculation of a standardized phase
angle (SPhA) aims to account for these confounding factors. A SPhA is calculated as a zscore which may be based on established population reference values stratified by a
combination of age, sex, BMI, or ethnicity (Barbosa-Silva et al. 2005; Barbosa-Silva,
Barros, and Larsson 2008; Bosy-Westphal et al. 2006; Kyle et al. 2001; Kyle et al. 2004).
PhA has been suggested to be a prognostic, health, functional and nutrition indicator (Ott
et al. 1995; Schwenk et al. 2000; Selberg and Selberg 2002). Generally, a low PhA
indicates cell membrane breakdown and thus an altered ability to store energy and
complete metabolic functions (Norman et al. 2012). Conversely, a high PhA indicates
intact cell membranes and high body cell mass (Norman et al. 2012). Thus, as PhA
reflects the quantity and types of tissues, such as muscle and fat mass, including
hydration status, it is hypothesized that PhA could reflect nutritional status. It is thought
that metabolic changes, such as those in cell membranes, are first affected by
malnutrition (Barbosa-Silva 2008). Thus, PhA may be able to detect malnutrition at an
early stage and may be useful in evaluating the effectiveness of nutrition therapy, before
improvements in nutritional status can be detected by other assessment methods such as
SGA. To this end, many studies have used PhA cut-off points to identify malnutrition
(Antunes et al. 2012; Selberg and Selberg 2002). Many of these PhA cut-off points were
derived using survival as its reference standard (Barbosa-Silva and Barros 2005;
Fernandes et al. 2012; Mattar 1995; Máttar 1996; Paiva et al. 2010). Thus, the reliability
of these cut-offs to identify malnutrition is unknown.
Therefore, the aim of this study is to evaluate the relationship between bioelectrical phase
angle and malnutrition severity as measured by the Subjective Global Assessment in
acute or chronically ill adults ≥18 years through a systematic review of cross-sectional
and/or retrospective studies.
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Methods
The systematic review protocol was registered on PROSPERO (no. CRD42016050876).
The current systematic review followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines. Studies were selected using the following
inclusion criteria: 1) original research published in English, 2) assessment of malnutrition
using SGA and its adapted versions, with comparison to PhA or SPhA, and 3) individuals
>18 years with acute or chronic disease/illness.

3.3.1

Data Sources

Relevant studies were identified by searching 7 electronic bibliographic databases:
Scopus, CINAHL, PubMed, ProQuest Nursing and Allied Health, Medline, Cochrane,
and ProQuest Dissertation and Thesis. Search terms used were ‘phase angle’ AND
(‘subjective global assessment’ OR SGA), including their MeSH terms. The search was
limited to human studies published in English through October 31, 2017. Reference lists
of all relevant studies, and relevant reviews were examined for other relevant studies,
although none were identified. Two investigators independently reviewed titles and
abstracts to select potentially eligible articles for document screening. If discordance
existed between the 2 reviewers, a decision was made by a third reviewer.
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Figure 2 Flowchart of selecting studies for the systematic review

3.3.2

Data Extraction and Synthesis

One reviewer independently extracted study information and then verified by a second
reviewer. Data was organized in an excel spreadsheet which included authors, year of
publication, country of origin, study objective, study population (clinical setting, sample
size, sex and age), subjective method(s) of nutritional assessment, BIA model used, PhA
cut-off, analyses between PhA and SGA and limitations of the study. A meta-analysis
was not performed as a variety of previously derived cut-off values were used which did
not allow for agreement statistics. Data were synthesized by disease group to allow for
more direct comparison between study results. Within each disease group, differences in
findings were compared and reasons for these differences such as heterogeneity, study
design, size and population were identified.
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3.3.3

Data Evaluation and Quality Assessment

The articles were evaluated by two reviewers using two quality assessment tools: the
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)
guidelines (Guyatt et al. 2011) and the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool (Whiting et al. 2011). The GRADE approach provides a
quality rating of scientific evidence ranging from Very Low to High. This approach is
widely used in systematic reviews and meta-analyses in the development of clinical
practice guidelines and health care recommendations (Guyatt et al. 2011). Although the
GRADE approach is a highly regarded tool, a second quality assessment tool designed
specific for diagnostic accuracy was also used to assess methodological quality. The
QUADAS-2 tool is recommended for use in systematic reviews involving diagnostic
accuracy studies. QUADAS-2 evaluates the risk of bias and applicability within four
domains observed in diagnostic accuracy studies: patient selection, index test, reference
standard and flow and timing. QUADAS-2 does not generate a quality score, instead it
allows the user to summarize the number of studies found at low, high or unclear risk of
bias and applicability across domains. To indicate an overall utility of PhA or SPhA as a
nutritional indictor in disease, quality assessment using the GRADE approach and the
QUADAS-2 tool was completed within each disease group separately and across all
studies. Both researchers involved in data extraction (SR and JM) were trained in the use
of GRADE guidelines and the QUADA-2 tool.
For the purposes of data extraction, articles with reported ĸ coefficients (kappa) were
interpreted as previously recommended by Altman (1991): ĸ < 0.20 (poor agreement);
0.21 ≤ ĸ ≤ 0.40 (fair agreement); 0.41 ≤ ĸ ≤ 0.60 (moderate agreement); 0.61 ≤ ĸ ≤ 0.80
(good agreement); ĸ > 0.80 (very good agreement) (Altman 1991).

Results
Database searches resulted in 298 articles. All articles were exported into a reference
management system and merged to remove duplicates, with 153 articles retained for
screening. A final 33 articles were identified as relevant and reviewed further. Publication
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years ranged from 1993 to 2017. Study characteristics are displayed in Table 1. Study
results are displayed in Table 2.

28

Table 1 Study characteristics of the literature on the comparison between PhA and SGA in malnutrition assessment

County

Participant
characteristics

Sample size
(% male)

Age (years)
mean ± SD,
medium (range)

BIA device

Austria

Years after Tx:
Group A: <5
Group B: 5-10
Group C: >10

Group A: n=11
Group B: n=19
Group C: n= 41
Sex not specified

Group A: 58 ± 8
Group B: 59 ± 6
Group C: 58 ± 10

RJL-101

(Bakshi and Singh
2016)

India

End-stage liver disease
patients admitted to
hospital for liver Tx

n=54
(n=20 underwent BIA)
Sex not specified

48.3 ± 10.2

MC-180MA
(Tanita)

(Peres et al. 2012)

Brazil

CLD

n=66 (57.6%M)

59 (41-79)

RJL-101

(Liboredo et al.
2015)

Brazil

Liver Tx

n=18 (83%M)

59 (41-79)

RJL Quantum
X

(Barbosa-Silva et
al. 2003)

Brazil

Preoperative elective
GI surgery

n=279 (31%M)

50.4 years

RJL Quantum
101

(Cardinal et al.
2010)

Brazil

Preoperative elective
GI surgery

n=125 (46.4%M)

M: 50.8
F: 51.0

Biodynamics
model 310

(Meireles et al.
2012)

Brazil

Preoperative elective
GI surgery

n=124 (43.5%M)

52.26 ± 14.95

Biodynamics
model 310e

Author, Year
Liver Disease
(Wagner et al.
2011)

Hospitalized Patients
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(Scheunemann et
al. 2011)

(Kyle et al. 2012)

(Kyle, Genton, and
Pichard 2013)

(Guerra et al.
2015)

(Norman,
Smoliner, et al.
2008)

Brazil

Switzerland

Switzerland

Portugal

Germany

Preoperative elective
GI surgery

Medical, surgical,
trauma patients

46.3 ± 13.6

Patients:
n=649 (59%M)

Patients:
M: 39.8 ± 12.7
F: 38.6 ± 14.1

Controls:
n=649 (59%M)

Patients:
n=983 (53%M)

Medical, surgical,
trauma and cancer
patients

Long and short LOS
hospitalized patients

n=98 (32.7%M)

Controls:
M: 39.7 ± 12.6
F: 38.4 ± 13.6
Patients:
M: 49.8 ± 19.7
F: 56.4 ± 23.2

Controls:
n=983 (53%M)

Controls:
M: 49.6 ± 19.6
F: 56.2 ± 22.9

Short LOS:
n=311 (45.2%M);

Short LOS:
55 (IQR 24)

Long LOS:
n=371 (54.8%M)

Long LOS:
61 (IQR 19)

Biodynamics
model 310e

RJL-101

RJL-101

Biodynamics
450

SGA-A: 60.3
(IQR 42.1-68.3)

Hospitalized gastroenterology, hepatology
and endocrinology
patients

n=242 (50%M)

SGA-B: 57.1
(IQR 33.5-66.4)
SGA-C: 56.2
(IQR 39.3-67.6)
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Nutriguard M
(Data Input)

Germany

Cardiology, general
surgery, hepatology,
endocrinology and GI
patients

n=777 (47%M)

53.6 ± 16.7

Nutriguard M
(Data Input)

(Gupta et al. 2004)

USA

Stage IV pancreatic
cancer

n=58 (60.3%M)
*SGA completed in
n=51

At diagnosis:
56.2 ± 1.5

RJL-101Q

(Gupta et al. 2008)

USA

Advanced CRC

n=73 (50.6%M)

At diagnosis:
56 ± 11.4

RJL-101Q

Group 1:
n=75 (48%M)

Group 1:
60.2 ± 12.2

(Stobäus et al.
2012)
Oncology

Group 1: Active gastric
or CRC

(Abe Vicente et al.
2013)

Brazil

Group 2: treatment
follow-up patients,
tumor free >3 months

Group 2:
n=62 (45.2%M)

Group 2:
61.3 ± 11.6

(Maurício et al.
2013)

Brazil

CRC

n=70 (44.3%M)

M: 60.1 ± 14.0
F: 60.7 ± 14.8

RJL Quantum
X

(da Silva et al.
2013)

Brazil

Patients with
esophageal and
stomach cancer

n=43 (60.5%M);

Not reported

Not reported

(MaleckaMassalska et al.
2016)

Poland

Newly diagnosed HNC

n=75 (89.3%M)

At diagnosis:
56.88 ± 8.21

SFB7 BioImp
v1.55
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Biodynamics
450

(Wladysiuk et al.
2016)

Poland

Presurgical, treatmentnaïve, HNC

n=75 (89.3%M)

56.88 ± 8.21

SFB7 BioImp
v1.55

(Mulasi et al.
2016)

USA

HNC patients after 3
months of chemoradiotherapy

n=19 (94.7%M)

59 ± 7

QuadScan
4000

(Maasberg et al.
2017)

Germany

Neuro-endocrine
neoplasia

n=203 (48.3%M)

Mean: 63.4

Nutriguard M
(Data Input)

(Norman et al.
2010)

Germany

Solid or hematologic
tumor disease

n=399 (52.1%M)

63.0 ± 11.8

Nutriguard M
(Data Input)

(Motta, Castanho,
and Velarde 2015)

Brazil

Pre-radiotherapy cancer
patients

n=93 (72%M)

62 ± 12.74

Biodynamics
450

(Guerra et al.
2015)

Brazil

Pre-dialysis patients
with Stage II-CKD

n=75;
Sex not specified.

64.8 ± 11.6

Biodynamics
450

(Passadakis et al.
1999)

India

CAPD

n=47 (55.3%M)

M: 58.9 ± 14.6
F: 56.2 ± 18.3

Not reported

(Gu et al. 2008)

China

CAPD

n=124 (41.1%M)

59.9 ± 12.8

Hydra analyzer
(Xitron Tech)

HD and CAPD

n=59 (64.4%M);
n=36 HD, n=23 CAPD

58 (25-80)

RJL-101

Renal Disease

(Enia et al. 1993)

Italy
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(Santin et al. 2018)

Brazil

HD

n=104 (70.2%M)

70.9 ± 6.9

Patients:
n=131 (49.6%M);

Patients:
61.6 ± 14.5

Controls:
n=272 (50%M)

Controls:
62.5 ± 13.6

Biodynamics
450
RJL-101
*Measured
post HD

(Maggiore et al.
1996)

Italy

HD

(Rimsevicius et al.
2016)

Lithuania

HD

n=99 (58.7%M)

58.7 ± 14.38

Biospace
InBody S10

(Vannini et al.
2009)

Brazil

HD

n=52 (67.3%M)

55 ± 13.6

Biodynamics
450

(de Oliveira et al.
2010)

Brazil

HD

n=58 (47.3%M)

49.22 ± 14.85

Not specified

CAPD: continuous ambulatory peritoneal dialysis; CKD: chronic kidney disease; CLD: chronic liver disease; CRC: colorectal
cancer; F: female; GI: gastrointestinal; HD: hemodialysis; HNC: head and neck cancer; LOS: length of stay; M: male; Tx:
transplantation.
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Table 2 Study results of the literature on the comparison between PhA and SGA in malnutrition assessment
Ref

SGA

PhA/SPhA
Results
cut-off

Agreement Analysis

Interpretation

Liver Disease

(Wagner et
SGA
al. 2011)

(Bakshi and
Singh 2016) SGA

(Peres et al. Adapted
2012)
SGA

<5.0°

<4.4˚normal,
4.4-5.4˚
borderline,
>5.4˚
abnormal

median
PhA
(5.18°)

Prevalence of
malnutrition:
Group A: 18.2% (SGA),
81.2% (PhA)
Group B: 10.5% (SGA),
31.6% (PhA)
Group C: 4.8% (SGA),
31.7% (PhA)

-

Prevalence of
malnutrition:
75% (PhA), 88.9% (SGAB+C)

ĸ=0.44 (90% agreement)
Sensitivity: 94.4%;
Specificity: 50%

Total:
5.18° (range: 1.86°-8.40°)
SGA-A:
5.31° (range: 3.45°-7.42°)
SGA-B+C:
4.35° (range: 1.86°-6.73°),
p=0.005
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-

No correlation between SGA and
PhA

Moderate agreement between
PhA and SGA

No significant difference
between sexes (p=0.59).
PhA was significantly reduced in
malnourished patients.

Prevalence of
malnutrition:
50% (PhA), 66.7% (SGA).
(Liboredo et Adapted
al. 2015) SGA

<5.44°

Total:
5.3° (range: 2.2°-6.9°);
SGA-A:
6.0° (range: 4.2°-6.9°);
SGA-B+C:
4.8° (range: 2.2°-6.1°), NS

-

Median PhA was not
significantly correlated with any
clinical parameter.
No significant difference in PhA
between SGA groups.

Hospitalized Patients

(BarbosaSilva et al. SGA
2003)

Male:
SGA-A: 6.65° [95% CI
(6.33°-6.98°)]
SGA-B: 6.13° [95% CI
(5.75°-6.50°)]
SGA-C: 4.70° [95% CI
(4.03°-5.36°)], p<0.001
<5.0°

ĸ=0.39 [95% CI (0.260.51)]
Male: ĸ=0.27 [95% CI
(0.07-0.47)]
Sensitivity: 31%;
Specificity: 97%

Female:
SGA-A: 6.36° [95% CI
(6.23°-6.50°)]
SGA-B: 5.14° [95% CI
(4.82°-5.46°)]
SGA-C: 4.22° [95% CI
(3.02°-5.43°)], p<0.001

Female: ĸ=0.46 [95% CI
(0.31-0.61)]
Sensitivity: 47%;
Specificity: 94%
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PhA significantly decreased with
worsening level of malnutrition
for the total sample and within
each sex group.
Fair agreement between SGA
and PhA in all participants and
males, and moderate agreement
in females.
Optimal PhA cut-off could not
be obtained. Cut-off with best
balance of sensitivity and
specificity was 6.3° (AUC: 0.72)
for males and 5.9° (AUC: 0.83)
for females.

Total:
ĸ=0.038 [95% CI
(-0.068-0.144)]
(Meireles et
SGA
al. 2012)

<-1.65 SD

Prevalence of malnutrition:
Male:
31.5% (SGA-B),
ĸ=0.041 [95% CI
4% (SGA-C)
(-0.135-0.216)]
4.8% (PhA)
Female:
ĸ=0.029 [95% CI
(-0.092-0.150)]
Total:
SGA-A: 0.3 ± 0.1 SD;
SGA-B+C: -0.8 ± 0.2 SD,
p<0.001

(Cardinal et
SGA
al. 2010)

<-0.8 SD

Male:
SGA-A: 0.3 ± 0.2 SD;
SGA-B+C: -0.7 ± 0.3 SD,
p=0.001

ĸ=0.45 [95% CI (0.25 to
0.65)]

SPhA was significantly reduced
in malnourished versus wellnourished patients.
Moderate agreement between
PhA and SGA in males, and fair
in all participants and females.

SPhA was significantly reduced
in malnourished versus wellnourished patients in the total
group and in each sex group.
Moderate agreement between
SPhA and SGA.

Female:
SGA-A: 0.3 ± 0.1 SD;
SGA-B+C: -1.0 ± 0.5 SD,
p=0.018
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(Scheuneman
SGA
n et al. 2011)

<-0.8 SD

Total:
SGA-A: 0.0 SD [95% CI
(-0.2-0.3)]
Total: ĸ=0.27 [95% CI
SGA-B+C: -0.7 SD [95% (0.06-0.48)]
CI (-1.2-0.2)], p=0.001
Sensitivity: 82.6%
Male:
Specificity: 40.6%
SGA-A: 0.1 SD [95% CI
Male:
(-0.4-0.6)]
SGA-B+C: -1.2 [95% CI ĸ=0.39 [95% CI (0.040.73)]
(-1.8-0.6)], p=0.002
Female:
Female:
ĸ=0.21 [95% CI (-0.04SGA-A: 0.0 [95% CI (0.47)]
0.3-0.3)]
SGA-B+C: -0.5 [95% (CI
-1.9-0.1)], NS
Male:
ĸ=0.489, p<0.001
AUC 0.83

Patients:
Male: 6.6° ± 1.1°
Female: 5.8° ± 0.96°,
p<0.001
(Kyle et al.
SGA
2012)

<4.6° F,
<5.0° M

Sensitivity: 73.3%;
Specificity: 76.6%

Controls:
Male: 7.55° ± 0.95°
Female: 6.5 ± 0.08°,
p<0.001

Female:
ĸ=0.412, p<0.001
AUC 0.8
Sensitivity: 64.5%;
Specificity: 76.1%
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Significant difference in SPhA
between malnourished and wellnourished groups in all patients
and male patients, but not in
female patients.
Optimal SPhA cut-off obtained
was -0.63 SD with 72.4%
sensitivity and 68.1% specificity.

PhA was significantly greater in
controls versus patients for both
sexes.
Moderate agreement between
PhA and SGA in males and
females.
Optimal PhA cut-offs were
determined to be <4.6° for
females and <5.0° for males.

Patients:
Male: 6.0° ± 1.4°
Female: 5.0° ± 1.3°,
p<0.05

(Kyle,
Genton, and SGA
Pichard
2013)

<4.6° F,
<5.0° M
(Kyle et al.
2012)

PhA was significantly greater in
controls versus patients for both
sexes.

Controls:
Male: 7.1° ± 1.2°
Female: 6.0 ± 1.2°,
p<0.05

-

SGA-A: RR 1.4 [95% CI
(1.0-2.1)], p=0.046

Patients with moderate
malnutrition were 3.8 times
more likely to have a low PhA
than healthy subjects.
Patients classified with severe
malnutrition were 7.2 times
more likely to have a low PhA
than healthy subjects.

SGA-B: RR 3.8 [95% CI
(2.9-4.9)], p<0.001
SGA-C: RR 7.2 [95% CI
(5.7-9.0)], p<0.001

(Guerra et
al. 2015)

PG-SGA

(Norman,
Smoliner, et SGA
al. 2008)

<4.6° F,
<5.0° M
(Kyle et al.
2012)

Prevalence of
malnutrition:
Short LOS, Long LOS
6.5%, 16.7% (PhA)
30%, 14% (SGA-B)
30%, 13% (SGA-C)

N/A

SGA-A:
5.39° (IQR 4.72°-6.05°)
SGA-B:
5.02° (IQR 4.42°-5.65°)
SGA-C:
4.17° (IQR 3.50°-5.20°)
SGA-A vs SGA-B,

ĸ=0.17
(60.5% agreement)

-
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Poor agreement between PhA
and SGA in both short and long
LOS.

PhA significantly decreased with
worsening level of malnutrition.

p=0.033
SGA-B vs SGA-C,
p<0.0001
SGA-C vs SGA-A,
p<0.001
Total: 4.91° ± 1.17°
(range, 1.62° - 8.51°; -7.2 2.5 SD)
PhA Linear regression:
SGA-B: ß=-0.538
(12.6% estimate of effect)
p<0.0001
(Stobäus et SGA
al. 2012)

N/A

SGA-C: ß =-0.935
(26.5% estimate of effect)
p<0.0001
SPhA Linear regression:

-

PhA was significantly greater in
males. PhA and SPhA were
significantly lower in
malnourished versus wellnourished patients.
Moderate and severe
malnutrition were significant
determinants of PhA and SPhA.

SGA-B: ß=-0.743
(27.2% estimate of effect)
p<0.0001
SGA-C: ß=-1.307
(58.2% estimate of effect)
p<0.0001
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Oncology Patients
(Gupta et al.
SGA
2004)

(Gupta et al.
SGA
2008)

(Abe
Vicente et
al. 2013)

median
PhA (5.0°)

Optimal
cut-off
determined

PG-SGA
<25th
validated
percentile
Portugues
(5.1°)
e version

(Maurício et
SGA
al. 2013)

Not
specified

Correlation: r=-0.26,
p=0.10

Median PhA:
SGA-A: 6.12°
SGA-B+C: 5.18°, p=0.005
Correlation: ρ=0.33,
p=0.004

-

No significant correlation
between PhA and SGA.

AUC=0.7 [95% CI (0.570.820)], p=0.005

PhA was significantly reduced in
malnourished versus wellnourished patients.

ROC curves:
PhA
<5.2°
<5.3°
<5.5°
<5.7°
<6.0°

Sens
51.7%
55.7%
58.6%
69.0%
82.8%

Spec
79.5%
68.2%
65.9%
56.8%
54.5%

Prevalence of malnutrition:
Group 1:
Group 1:
Sensitivity: 44%;
66.6% (PG-SGA); 36%
Specificity: 80%
(PhA)
Group 2:
Group 2:
Sensitivity: 38.4%;
30.9% (PG-SGA); 14.5%
Specificity: 91.2%
(PhA)
SGA-A: 5.5° ± 0.6°
SGA-B: 5.4° ± 1.0°
SGA-C: 4.9° ± 1.1°,
*p<0.05 between SGA-A
and SGA-C

ĸ=0.11, p<0.05

Fair agreement between PhA and
SGA.
PhA cut-off 5.9° in males with
progressive disease had the best
balance of sensitivity (100%)
and specificity (73.3%)

Significant association between
PhA and PG-SGA in Group 1
(p=0.041) and Group 2
(p=0.006)

PhA was significantly reduced in
severely malnourished versus
well-nourished patients only.
Poor agreement between PhA
and SGA.
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(da Silva et
al. 2013) SGA

th

<5
percentile
(-1.65 SD)

SGA-A: 6.7° (5.6-7.4)°
SGA-B: 5.1° (3.8-6.0)°
SGA-C: 4.5° (2.6-6.4)°
SGA-A: vs SGA-C,
p<0.05

PhA was significantly reduced in
malnourished versus wellnourished patients.

ĸ<0.20

Poor agreement between SGA
and PhA.

SGA-A vs SGA-B, p<0.05
SGA-B vs SGA-C, NS

(MaleckaMassalska et
al. 2016) SGA

(Wladysiuk et
SGA
al. 2016)

(Mulasi et al.
PG-SGA
2016)

Optimal
cut-off
determined

Total: 5.04° ± 0.88°,
SGA-A: 5.25° ± 0.76°,
SGA-B+C: 4.73° ± 0.96°,
p=0.0009

Optimal cut-off point
PhA was significantly reduced in
(4.733°):
malnourished versus wellAUC=0.7 [95% CI (0.57nourished patients.
0.82)], p=0.005
Optimal PhA cut-off point was
Sensitivity: 80%;
<4.733°.
Specificity: 56%

median
PhA
(4.733°)

SGA-A: 5.25° ± 0.76°;
SGA-B+C: 4.73° ± 0.96°,
p=0.0009
Correlation: r=-0.35,
p=0.0022

PhA was significantly reduced in
malnourished versus wellnourished patients. PhA was
negatively correlated with
worsening SGA score.

N/A

PG-SGA-A: 5.5° ± 0.96°
PG-SGA-B+C: 5.3° ±
0.84°, p=0.62
Correlation: r=-0.35,
p<0.01

-

-

No significant difference in PhA
between well-nourished and
malnourished patients.
PhA was negatively correlated
with worsening SGA score.
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Total:
SGA-A: 5.3°
SGA-B+C: 4.2°, p<0.001

(Maasberg et
SGA
al. 2017)

Male:
SGA-A: 5.4° ± 1.0°
SGA-B+C: 4.5° ±1.1°,
p<0.05

N/A

-

PhA was significantly reduced in
malnourished versus wellnourished patients.

-

Patients with a high SPhA had
1.5 times lower odds of being
classified as moderately
malnourished and 2.2 times
lower odds of being classified as
severely malnourished than the
odds of being identified as wellnourished.

Female:
SGA-A: 5.1° ± 0.8°
SGA-B+C: 4.0° ±1.1°,
p<0.05
Total: 4.59° ± 1.12°
Male: 4.70° ± 1.17°,
Female: 4.47° ± 1.04°,
p<0.043
(Norman et
al. 2010)

th

SGA

PhA <5
percentile

Multinomial logistic
regression:
SPhA and SGA-B:
OR 0.633 [(95% CI
(0.504-0.794)], p<0.0001
SPhA and SGA-C:
OR 0.449 [(95% CI
(0.337-0.597)], p<0.0001
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(Motta,
PG-SGA; <-1.65 SD;
Castanho,
and Velarde PG-SGA Optimal
2015)
categorica cut-off

l

Median PhA/SPhA:
5.95° ± 1.00°; -1.04 ± 0.98
SD

determined

Median PG-SGA score: 4
±4

N/A

SGA-A: 6.4° ± 0.7°
SGA-B: 5.6° ± 0.9°
SGA-C: 5.3° ± 0.6°,
p<0.01
SGA-A versus SGA-B,
p<0.05
SGA-A versus SGA-C,
p<0.05
SGA-B versus SGA-C,
NS

PhA and PG-SGA (5.9°):
ĸ=0.25
AUC=0.72 [95% CI
(0.61-0.83)]

Fair agreement between SPhA
and PG-SGA, and SPhA and
PG-SGA categorical.

Optimal PhA cut-off points
PhA and PG-SGA
using PG-SGA and PG-SGA
categorical (5.4°): ĸ=0.26
categorical as gold standard were
AUC=0.84 [95% CI (0.69<5.9° and <5.4°, respectively.
0.99)]

Renal Disease

(Guerra et al.
SGA
2015)

(Passadakis
SGA
et al. 1999)

-

No significant difference in PhA
between males and females.

Male: PhA=5.06° ± 1.3°
Females: 4.79° ± 1.4°,
p=0.56
N/A

PhA was significantly reduced in
mildly and severely
malnourished patients as
compared to well-nourished
patients, but, there was no
significant difference between
mildly and severely
malnourished patients.

PhA was significantly reduced in
mildly and moderately
malnourished patients as
compared to well-nourished
patients, however, there was no
significant difference in PhA

SGA-A: 5.41° ± 1.15°,
SGA-B: 4.62° ± 1.21°,
SGA-C: 3.5° ± 1.53°
A versus B, p=0.087
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A versus C, p=0.021
B versus C, p=0.193

(Gu et al.
2008)

SGA

N/A

Spearman's rank test:
R=0.48, p=0.0048

between mildly and moderately
malnourished patients. PhA was
negatively correlated with
worsening SGA-score.

SGA-A: 4.79° ± 1.04°;
SGA-B+C: 3.83° ± 0.86°,
p<0.001

PhA was significantly reduced in
malnourished versus wellnourished patients.

Male:
SGA-A: 6.32° ± 1.37°;
SGA-B+C: 4.56° ± 0.91°,
p<0.001
Female:
SGA-A: 5.76° ± 1.26°;
SGA-B+C: 4.02° ± 0.72°,
p=0.009
(Enia et al.
1993)

SGA

N/A

CAPD:
SGA-A: 4.82° ± 0.78°;
SGA-B+C: 4.05° ± 0.49°,
p=0.016
HD:
SGA-A: 6.76° ± 1.06°;
SGA-B+C: 4.76° ± 1.05°,
p<0.001
Univariate analysis: r=0.58, p<0.001
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PhA was significantly reduced in
malnourished versus wellnourished patients in each sex
group and in CAPD and HD
groups.
In total sample, PhA was
negatively correlated with
worsening SGA-score.

Linear regression
coefficient of the repeated
measures model in time:
(Santin et al.
7p-SGA
2018)

N/A

(Maggiore et
SGA
al. 1996)

lower
quartile
and <10th
percentile
to identify
SGA-C

(Rimseviciu
s et al. 2016) SGA

Optimal
cut-off
determined

1-unit increase in 7p-SGA was
significantly associated with an
increase of 0.05° and 0.39° in
PhA for males and females,
respectively.

Male: ß=0.05 (0.02 SE),
p=0.03
Female: ß=0.39 (0.11 SE),
p=0.002
*adjusted for age and
dialysis vintage
Lower quartile cut-off:
Sensitivity: 67%
Specificity: 78%

Spearman's rank
correlation coefficient:
rs=-0.43, p≤0.01

<10th percentile cut-off:
Sensitivity: 91%
Specificity: 33%

Optimal PhA cut-offs:
SGA-B: <25th percentile
AUC 0.70 [95% CI
(0.60-0.81)], P=0.01)

Multivariate analysis:
OR 3.69 [95% CI (1.598.62)], p=0.002

SGA-C: <15th percentile
AUC 0.74 [95% CI
(0.62-0.85)], P=0.005)
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PhA was negatively correlated
with worsening SGA-score.

Mild malnutrition was most
accurately identified by PhA
<25th percentile. Severe
malnutrition was most accurately
identified by PhA <15th
percentile.
Patients with a higher PhA had
3.68 times lower odds of being
classified as malnourished than
the odds of being identified as
well-nourished.

(Vannini et al.
7p-SGA
2009)

median
PhA
(<6.4°)

SGA;
AdaptedSGA
(de Oliveira
(Kalantar- <5.0°
et al. 2010)
Zadeh et
al. 1999);
PG-SGA

No significant difference
between malnourished and wellnourished patients.

SGA-A: 6.76° ± 1.4°
SGA-B+C: 6.2° ± 1.7°,
p=0.10
Multivariate analysis:
OR = 0.42, p=0.011

Patients with a higher PhA had
2.4 times lower odds of being
classified as malnourished than
the odds of being identified as
well-nourished.

Total: 6.19° ± 1.33°
Male: 6.70° ± 1.23°;
Female: 5.73° ± 1.27°,
p=0.005

PhA was significantly higher in
males versus females.
SGA and PhA: ĸ=0.316

Linear correlation:
Adapted SGA and PhA:
r=-0.533, p<0.001

Moderate agreement between
PhA and adapted SGA.
PhA was negatively correlated
with worsening adapted SGA
and PG-SGA scores.

PG-SGA and PhA:
r=-0.453, p<0.001

AUC: area under the curve; CAPD: continuous ambulatory peritoneal dialysis; HD: hemodialysis; NS: not significant; OR: odds
ratio; PhA: phase angle; ROC: receiver operator characteristics; SE: standard error; SGA-A: well-nourished; SGA-B: mildmoderately malnourished; SGA-C: severely malnourished; SPhA: standardized phase angle
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3.4.1

Liver Disease

Four studies included participants with liver disease, two in chronic liver disease, one in
pre-transplant (Tx) patients and one in post-Tx patients. Two additional studies were
identified which assessed both SGA and PhA, however, all patients were assessed as
SGA-A which did not allow for any direct comparison between SGA-score and PhA.
Thus, these two articles were not included in this systematic review (Nunes et al. 2016;
Saxena, Sharma, and Gupta 2016).
Two studies aimed to identify malnutrition using predetermined PhA cut-offs. Wagner et
al. (2011) found a PhA cut-off of <5° in individuals post liver Tx did not correlate with
SGA, and malnutrition was underestimated by SGA compared with PhA cut-offs. While
Bakshi and Singh (2016) reported a moderate agreement between SGA and a PhA cut-off
of <4.4° in hospitalized, end-stage liver disease patients. Additionally, Peres et al. (2012)
found that PhA was significantly higher (p=0.005) in well-nourished patients compared
to malnourished patients with chronic lung disease (CLD). Whereas, in a small study of
eligible transplant patients with cirrhosis, no significant difference (p>0.05) was found
between the mean PhA of well-nourished and malnourished patients (Liboredo et al.
2015). In summary, an association between PhA and SGA within liver disease patients is
not clear. Although a trend toward decreasing PhA with worsening malnutrition exists,
most studies found no correlation between PhA and SGA.

3.4.2

Hospitalized Patients

Nine studies involved hospitalized patients with a variety of clinical conditions. In
preoperative GI patients, Barbosa-Silva et al. (2003) found a moderate agreement
(ĸ=0.39) between SGA and a PhA cut-off of <5.0°, however, optimal cut-offs of 6.3°
and 5.9° in males and females, respectively, had the best balances of sensitivity and
specificity. Using a SPhA cut-off of <-1.65 SD, Meireless et al. (2012) found a weak
agreement in females and a moderate agreement in males between SGA and SPhA. Two
studies used a SPhA of <-0.8 SD. Cardinal et al. (2010) found a moderate agreement
between SGA and SPhA, while Scheunemann et al. (2011) found weak agreements in the
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total sample and each sex-group. As well, Scheunemann et al. (2011) determined an
optimal SPhA cut-off of <-0.63 SD.
In medical, surgical and trauma patients, Kyle et al. (2012) determined an optimal PhA
cut-off of <5.0° for men and <4.6° for women. Using these cut-offs, Kyle et al. (2013)
found that the relative risk of low PhA increased with worsening malnutrition and Guerra
et al. (2015) reported a 60.5% agreement with PG-SGA in both long and short stay
hospitalized patients. In GI, hepatology, endocrinology, cardiology and general surgery
patients, Norman et al. (2008) found that PhA was significantly reduced with worsening
nutrition status (p<0.05). Stobaus et al. (2012) found reduced SPhA with worsening
nutrition status. Overall, the body of research in hospitalized patients shows a significant
reduction in PhA and/or SPhA with worsening malnutrition assessed using SGA. Despite
this, agreement between the two methods ranged from weak to moderate as a variety of
different PhA and SPhA cut-offs were used.

3.4.3

Oncology

Eleven studies were identified in oncology patient populations. Diagnoses included
pancreatic cancer, gastric cancer (GC) and colorectal cancer (CRC), neuroendocrine
neoplasia, and head and neck cancers (HNC). In patients with pancreatic cancer, Gupta et
al. (2004) found a non-significant weak negative correlation between PhA and SGA (r=0.26, p=0.10). Gupta et al. (2008) found that median PhA of well-nourished patients was
significantly greater (p=0.005) than that of malnourished patients in advanced CRC
patients. Authors were only able to determine an optimal PhA cut-off of <5.9° in males.
Vicente et al. (2013) found a significant association between malnutrition identified using
PG-SGA and a PhA cut-off of <5.1° (p=0.041) in patients with active GC and CRC, and
those tumor free for >3 months. Mauricio et al. (2013) found a weak agreement between
SGA and SPhA in CRC patients, and only a significant difference in SPhA between the
well-nourished and severely malnourished group (p<0.05). da Silva et al. (2013) also
found a weak agreement between SGA and a SPhA cut-off <-1.65 SD in esophageal and
GC patients.
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Three studies were completed in HNC patients. Malecka-Massalska et al. (2016) found
that PhA was significantly higher in well-nourished patients than in malnourished
patients (p=0.0009) and an optimal cut-off of 4.733° was determined. Wladysiuk et al.
(2016) also found significant difference between PhA in well-nourished and
malnourished patients (p=0.0009), and PhA was found to be negatively correlated with
SGA (r= -0.35, p=0.0022). Whereas, Mulasi et al. (2016) found no significant difference
between PhA in well-nourished patients and malnourished patients (p=0.62) however,
had a negative correlation of r=-0.35 (p<0.01).
Maasberg et al. (2017) assessed malnutrition in patients with neuroendocrine neoplasia
using SGA and PhA. Mean PhA was significantly higher (p<0.001) in the well-nourished
group as compared to the malnourished group and continued to be significant when
stratified by sex (p<0.05). Norman et al. (2010) studied the relationship between SPhA
and SGA in patients with cancerous tumors. SPhA had a strong positive effect on SGA-B
(p<0.0001), and SGA-C (p<0.0001). Using a SPhA cut-off <-1.65 SD, Motta et al. (2015)
found fair agreement between SPhA and PG-SGA, and SPhA and PG-SGA categorical.
An optimal PhA cut-off of <5.9° was determined using PG-SGA as the reference method,
and <5.4° using PG-SGA categorical as the reference method. Articles with a broad range
of cancer diagnoses were identified in our search. Although studies reported significant
agreements between PhA and/or SPhA with SGA, strengths of agreements ranged from
fair to poor.

3.4.4

Renal Disease

Nine studies included participants with renal disease, including predialysis chronic
kidney disease (CKD), continuous ambulatory peritoneal dialysis (CAPD) patients and
hemodialysis (HD). Guerra et al. (2015) found a significant difference in PhA between
well-nourished and malnourished groups (p<0.05), but not between mildly and severely
malnourished groups (p>0.05) in pre-dialysis patients with Stage II-CKD. Two studies
evaluated PhA in patients on CAPD. One study by Gu et al. (2008) found that PhA was
significantly higher in well-nourished as compared to malnourished patients (p<0.001).
While Passadakis et al. (1999) found that PhA was only significantly different between
well-nourished and severely malnourished groups (p=0.021) with a weak correlation
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(r=0.48, p=0.0048) between SGA and PhA. Enia et al. (1993) found that PhA was
significantly higher in well-nourished patients than in malnourished patients in both HD
and CAPD patient groups with a significant negative correlation of r=-0.58 between SGA
and PhA, (p<0.001). In HD patients, Santin et al. (2017) found that for every 1-unit
increase in 7p-SGA PhA (improved nutritional status) was associated with an increase of
0.05° in males and 0.39° in females, respectively.
Four studies analyzed PhA cut-offs in HD patients. Maggiore et al. (1996) found that a
PhA cut-off of <25th percentile used to identify severe malnutrition had a 67% sensitivity
and 78% specificity. However, a lowered cut-off of <10th percentile had an improved
sensitivity of 91% but a reduced specificity of 33%. Rimsevicius et al. (2016) found that
moderately and severely malnourished patients were most accurately identified by
adjusted PhA cut-offs of <25th and <15th percentile, respectively. Vannini et al. (2009)
used a PhA cut-off of <6.4° and found no significant difference between mean PhA of the
well-nourished and malnourished groups (p=0.10) but had an odds ratio of 0.42
(p=0.011). de Oliveira et al. (2010), found that PhA had a significant negative linear
relationship with QSGA and PG-SGA, and a moderate agreement with SGA using a PhA
cut-off of <5.0°. Although no studies used SPhA in their analyses, the majority of studies
in the renal disease population reported significant trends of decreased PhA with
worsening malnutrition.

3.4.5

Quality Assessment

Evidence quality was assessed by both GRADE Guidelines and the QUADAS-2 tool.
Results of the quality assessment using the GRADE guidelines are shown in Table 3.
Results of the quality assessment using the QUADAS-2 tool are shown in Figure 3.
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Table 3 Summary of Findings
Bioelectrical phase angle compared to Subjective Global Assessment as an
indicator of malnutrition
Patient or Population: acute or chronically ill adult patients
Setting: inpatient and outpatient
Intervention: Measurement of phase angle
Comparison: Subjective Global Assessment
Number of
Patient
Outcome
Participants
Quality and Justification
Population
(Studies)
246
●○○○ Very
Liver Disease
(4 cross-sectional
Low1,2
studies)
3717 + 1632
Hospitalized
controls
●●●○
Patients
(9 cross-sectional
Moderate3,4
Relationship
studies)
between
●●○○
PhA/SPhA
1238 (2
Low1,2,4
and SGA
retrospective chart
●●●○
Oncology
reviews + 9 crossModerate3,4
sectional studies)
749 + 272 controls
(1 longitudinal + 8
Renal Disease
●●○○ Low2,4
cross-sectional
studies)
1
Inconsistency in results
2
Risk of bias: no sex comparison, minimal to no use of SPhA
3
Large magnitude of effect: significant difference in PhA between well-nourished and
malnourished patients
4
Dose response – PhA significantly decreases with worsening malnutrition (SGA-B vs
SGA-C)
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Figure 3 QUADAS-2 Results.
The proportion of studies with low, high and unclear risk of bias and concerns regarding
applicability between the index test (PhA) and SGA are shown according to QUADAS-2
domains. a) Overall, 61% of studies had high risk of bias of the index test, PhA, and 9%
of studies had high concerns for the applicability of the index test, b) Liver disease: Due
to the lack of any PhA standardization methods, 100% of the articles reviewed had a high
risk of bias of the index test, PhA c) Oncology patients: 34% of studies had high risk of
bias of the index test. d) Hospitalized patients - 64% of studies had high risk of bias in
the use of PhA. Two studies (22% of studies) had concerns related to the applicability of
the index test due to exclusion of participants where PhA measurement and SGA would
have been appropriate. These studies excluded participants based on the inability to
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obtain anthropometric parameters due to patients being bedridden. e) Renal disease Only a third of articles (Figure 3e) attempted to control for confounding factors through
testing for sex differences or analyzing results by sex, therefore 67% of studies had high
risk of bias of the index test. 11% of studies had concerns related to the applicability of
the index test due to exclusion of participants where PhA measurement and SGA would
have been appropriate.

Discussion
This study aimed to evaluate the relationship between bioelectrical phase angle and
malnutrition severity as measured by the Subjective Global Assessment in acute or
chronically ill adults. Many studies used different PhA cut-offs, for example, sample
median, lower quartile or cut-offs determined from previous studies which may not be
translatable to all disease states. As the full biological meaning of PhA is not understood
it would be difficult to predict how PhA may vary by disease even with controlling for
confounding factors such as nutrition status, weight, age or gender. It is difficult to say
with certainty that PhA cut-offs determined within one disease state, or based on nonnutritional parameters such as survival, are appropriate in all clinical situations.
Therefore, the overall evidence quality determined in this systematic review received a
grade of Low.
Many nutritional assessment tools exist; however, their use within specific disease
populations can be limited. Within liver disease, complications such as fluid retention and
hypoproteinemia associated with hepatic deterioration can confound nutritional
assessment techniques such as BIA, biochemical markers, and BMI (Tynan and Hasse
2004). Use of SGA in CLD is recommended by the European Society for Parenteral and
Enteral Nutrition to screen for malnutrition in liver disease including alcoholic
steatohepatitis, cirrhosis, surgery, and transplantation (Plauth et al. 2006). A recent
review also identified SGA as a tool to use in nutritional assessment in liver cirrhosis
(Tandon et al. 2017). Despite its acknowledged limitations in individuals with ascites,
European Society for Parenteral and Enteral Nutrition recommends PhA to quantify
undernutrition in cirrhosis, and in liver transplantation and surgery and PhA is said to be
superior to anthropometry and 24 hour creatinine excretion (Plauth et al. 2006).
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Interestingly, in these guidelines, the use of SGA in CLD received an evidence grade of
C, while the use of PhA received a grade of B. Additionally, clinical practice guideline
recommendations, evidence quality of the use of PhA in malnutrition assessment received
the lowest grade.
Hospital malnutrition is a well-established issue (Butterworth 1974), and has been
associated with pressure ulcers, infection, impaired wound healing, increased length of
hospital stay and readmission risk, all of which create a greater burden on health care
costs and, ultimately, quality of life for patients (Tappenden et al. 2013). The American
Society for Parenteral and Enteral Nutrition and European Society for Parenteral and
Enteral Nutrition have recommended routine use of nutrition screening to identify
malnutrition in hospitalized patients, including using SGA (Kondrup et al. 2003; Mueller
et al. 2011). Currently, no published guidelines have identified the use of PhA in
malnutrition screening or assessment.
Many elements of kidney disease such as fluid retention can complicate clinical
assessments and jeopardize nutrition (de Oliveira et al. 2010). The utility of PhA and
other BIA measures in dialysis patients is limited due to overhydration pre-dialysis and
body water compartments not yet in steady state immediately post-dialysis. The National
Kidney Foundation’s Kidney Dialysis Outcomes Quality Initiative clinical guidelines
have identified the need for frequent nutrition assessment and recommend SGA as a valid
and clinically useful tool in the overall nutritional assessment of non-dialyzed and
dialyzed individuals (Johansen et al. 2001). The National Kidney Foundation’s Kidney
Dialysis Outcomes Quality Initiative guidelines recommend The CANADA-USA
Peritoneal Dialysis Study Group Study’s 7p-SGA (Churchill, Taylor, and Keshaviah
1996) as the preferred SGA technique. The National Kidney Foundation’s Kidney
Dialysis Outcomes Quality Initiative identify valid methods of protein-energy
malnutrition through anthropometric analysis, however, use of BIA in nutrition
assessment is not mentioned in these guidelines. More recently, the 2010 Chronic Kidney
Disease (CKD) Evidence-Based Nutrition Practice Guideline (The American Dietetic
Association 2010) from Academy of Nutrition and Dietetics concluded that any valid
measurement methodology including anthropometrics and body compartment estimates
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such as dual energy x-ray absorptiometry or BIA, are appropriate in CKD. However, as
no reference standard for assessing body composition in CKD patients has been
established, no one test has been shown to be superior to another with respect to assessing
body composition.
Nutrition status in oncology patients can be affected by surgery, radiation and
chemotherapy treatment as well as the pathophysiology of cancer itself (Lis et al. 2012).
Prevalence of malnutrition is estimated to range between 50-80% depending on cancer
diagnosis (Lis et al. 2012). Clinical practice guidelines have recommended the use of
SGA and PG-SGA in the oncology population (August, Bozzetti, and Huhmann 2009;
Fearon et al. 2011). As well, in their review of available tools within the adult oncology
population, the Academy of Nutrition and Dietetics’ Oncology Expert Work Group
identified both the SGA and PG-SGA as valid and reliable tools in nutrition diagnosis
within ambulatory and acute care settings (Nutrition and the Adult Oncology Patient
2013). No published guidelines have identified use of PhA in malnutrition screening or
assessment.
Standardizing PhA with reference values for healthy populations may work to resolve
this issue of PhA variation through accounting for individual variations from population
norms (Norman et al. 2010). Thus, SPhA allows for results that are translatable and
comparable between studies and disease states. Of the 33 articles identified in this
systematic review, only nine used SPhAs. Despite SPhA providing greater rigor than
absolute values of PhA alone, variation can still exist based on the reference data used.
For example, population norms determined in a German population (Bosy-Westphal et al.
2006) may be different than those determined in a Brazilian population (Barbosa-Silva,
Barros, and Larsson 2008). Population norms can be standardized in a number of
different ways. For instance, most published norms are presented in age- and sexstratified groups, with fewer studies also including or ethnicity. Future research should
make use of a SPhA, however, published data on PhA norms reflecting more diverse
populations is needed. Thus, careful consideration is necessary when choosing
appropriate reference values within existing population data.
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Only six studies attempted to determine an ideal PhA or SPhA cut-off to diagnose
malnutrition using SGA as the reference standard. Within hospitalized patients, one study
identified a SPhA cut-off of <-0.63 SD (Scheunemann et al. 2011), while two studies
suggested gender-specific cut-offs of <6.3° in males and <5.9° in females (Barbosa-Silva
et al. 2003), and <5.0° in males and <4.6°in females, respectively (Kyle, Genton, and
Pichard 2013). Within cancer patients, suggested PhA cut-off values included <4.733°
(Malecka-Massalska et al. 2016), <5.9° (Motta, Castanho, and Velarde 2015), <5.4°
(Motta, Castanho, and Velarde 2015), and <5.9° ( Gupta et al. 2008) in males with
progressive disease. Although other PhA and SPhA cut-offs exist, it is important to note
that other cut-offs present in the literature may have been determined using non-nutrition
related reference standards limiting their ability to accurately identify malnutrition.
Limitations of SGA-derived PhA or SPhA cut-offs, such as their diagnostic accuracy,
should not be overlooked. Additionally, we acknowledge that including only articles
published in English can bias the results found in this systematic review.
A limitation of using a single PhA or SPhA cut-off value is that it restricts an individual’s
nutrition status into two binary categories: well-nourished or malnourished. Rather,
nutrition status exists on a spectrum. One small study (n=20) identified in this review
used two PhA cut-offs to classify patients into three categories; normal, borderline and
abnormal (Bakshi and Singh 2016). However, no patients were identified as having
borderline PhAs, therefore, no comparison was made between comparable SGA-B and
borderline PhA groups. Thus, in addition to controlling for confounding factors using a
SPhA, and carefully choosing an appropriate cut-off value, future research should attempt
to identify varying degrees of malnutrition using multiple SPhA cut-offs.
A major limitation of this review is attempting to find a meaningful relationship between
two methodologies that may both be influenced by the operator. However, many studies
have already used PhA as a nutritional marker to diagnose malnutrition despite its lack of
validation. Therefore, it is important to comprehensively study the appropriateness of its
use in both research and clinical practice. The current body of research indicates that PhA
cannot independently identify malnutrition in disease, however, PhA or SPhA may show
more promise in its use within nutrition monitoring. As an objective measure, SPhA may
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be able to detect more sensitive changes in nutrition status as compared to other nutrition
assessment tools, which can be useful in assessing effectiveness of nutrition
interventions. However, further research is needed to explore the relationship between
nutrition status and PhA over time.

Conclusion
Early identification of malnutrition or the risk of malnutrition is vital in order to provide
appropriate nutrition therapy as preventing worsening malnutrition or correcting
nutritional deficiencies can help improve overall nutritional status and prognosis. Thus,
the idea of a simple, quick and objective measure to identify malnutrition is appealing.
Although the results of this systematic review are sufficiently encouraging to warrant
further research in utilizing PhA, we are not able to conclude that PhA can independently
identify malnutrition in disease.
Future research using PhA in nutritional assessment should focus on utilizing a
standardized PhA. Additionally, further research should investigate the change in SPhA
over time to determine if improvement or decline in nutritional status will affect SPhA.
Within a clinical practice perspective, inclusion of SPhA in nutritional assessment can
complement other nutrition assessment methods, as one method alone may not be
sensitive enough to capture all factors that influence nutritional status.
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Chapter 4
4

Exercise Capacity and its Relationship with Body
Composition and Nutrition Status in Patients with
Interstitial Lung Disease
Abstract

Background: Individuals with interstitial lung disease (ILD) are known to have
diminished exercise ability. In ILD, neither the impact of body composition nor nutrition
status on functional exercise capacity has been fully explored. The primary objective of
this study was to explore the relationship between nutrition status and body composition
parameters with exercise capacity in a cohort of patients with fibrotic ILD. Our second
objective focused on assessing the appropriateness of surrogate markers of nutrition
status in ILD patients. Methods: Seventy-eight patients diagnosed with fibrotic ILD were
recruited from the ILD clinic in London, Ontario, Canada. Lung function was determined
by % predicted forced vital capacity (%FVC). Exercise capacity was determined the 6minute walk distance (6MWD). Nutrition status was assessed using the validated
subjective global assessment (SGA), standardized phase angle (SPhA) and impedance
ratio z-score (z-IR). Body composition parameters fat-free mass index z-score (z-FFMI)
and body fat mass index z-score (z-BFMI) were determined using bioelectrical
impedance analysis. Results: A total of 57% of participants were moderately to severely
malnourished according to SGA. z-FFMI (r=0.42, p=0.02) and SGA (r=0.49, p<0.01)
were significantly associated with 6MWD independent of %FVC. Age [OR 1.1, CI 95%
(1.01-1.25), p=0.04], low body mass index [OR 0.73, 95% CI (0.57-0.92), p=0.01], zFFMI [OR 0.34, CI 95% (0.17-0.68), p<0.01], z-BFMI [OR 0.39, CI 95% (0.17-0.91),
p=0.03] were significantly associated with severe malnutrition (SGA-C). SPhA did not
show to be a surrogate marker of nutrition status in our sample, however, mean z-IR was
significantly greater in the severe malnutrition group compared to the well-nourished
(p<0.01) and moderate malnutrition (p=0.04) groups. A higher z-IR significantly
increased the odds of severe malnutrition [OR 2.75, 95% CI (1.27-6.03), p=0.02].
Conclusion: Decreased z-FFMI and SGA-C independent of lung function were
significantly associated with exercise capacity in fibrotic ILD. z-IR was significantly
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greater in severe malnutrition versus the well-nourished group indicating worsened cell
health in severe malnutrition.

Introduction
Individuals with interstitial lung disease (ILD) are known to have limited exercise ability
(Mendes et al. 2015), which can significantly impact their ability to participate in normal
activities of daily living, compromising their quality of life (Hansen and Wasserman 1996;
Mendes et al. 2015). Diminished exercise capacity in ILD is multifaceted including
pathophysiological factors such as impaired gas exchange, altered respiratory mechanics,
limited pulmonary circulation and peripheral muscle dysfunction (Holland et al. 2008;
Raghu et al. 2011).
The six minute walk test is a reliable and validated tool in ILD patients routinely used to
measure functional exercise capacity, or in other words, the functional level of exercise of
everyday physical activities (Du Bois et al. 2011; Eaton et al. 2005; Lederer et al. 2006;
Serajeddini, Rogliani, and Mura 2018). A decline in 6-minute walk distance (6MWD)
predicts both poor survival and mortality in patients on a lung transplant waitlist (Du Bois
et al. 2011; Lederer et al. 2006). The 6MWD has high prognostic value as it is independent
from lung function (Serajeddini, Rogliani, and Mura 2018).
In other chronic lung diseases, such as chronic obstructive pulmonary disease (COPD),
poor nutrition status has a negative effect on exercise capacity and muscle dysfunction
(Sabino, Silva, and Brunetto 2010; Shan et al. 2015). As well, nutrition intervention and
education have the potential to improve exercise capacity in COPD patients (Hill,
Vogiatzis, and Burtin 2013; Steiner et al. 2003). However, in ILD, no studies have assessed
the relationship between nutrition status and exercise capacity, nor has the potential for
nutrition intervention in ILD as part of pulmonary rehabilitation been established.
Components of overall nutrition status, such as body mass index (BMI), and more recently
lean body mass, have been shown to be predictors of survival in patients with idiopathic
pulmonary fibrosis (IPF), a common component of ILD. In ILD, neither the impact of low
fat-free mass nor nutrition status on functional exercise capacity have been fully explored.
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The primary objective of this study was to explore the relationship between nutrition status
assessed using the subjective global assessment (SGA), and body composition parameters
assessed using bioelectrical impedance analysis (BIA) with exercise capacity in a cohort
of patients with fibrotic ILD. Since obtaining SGA requires trained personnel, who may
not be readily available as part of standard ILD care, our second objective focused on
assessing the appropriateness of surrogate markers of nutrition status, such as standardized
phase angle (SPhA) and impedance ratio (IR), in ILD patients.

Methods
4.2.1

Study Population

In this cross-sectional study, patients diagnosed with fibrotic ILD (n=78) were recruited
from the ILD clinic in London, Ontario, Canada. Inclusion criteria included ambulatory
patients over 18 years of age attending an ILD clinic. Patients were excluded according to
the following criteria: inability to provide consent due to communication issues (cognitive
and motor), presence of cardiac implantable electrical devices, non-stable ILD patients
defined as those with infections and/or fever, admitted to hospital in the previous month,
presence of an unstable co-morbid illness or combined pulmonary fibrosis and emphysema
(CPFE). The study protocol was approved by the Western University Research Ethics
Board (protocol n. 104028).

4.2.2

Diagnosis and Disease Severity

The presence of fibrotic ILD was defined based on high-resolution chest computed
tomography scan and compatible pulmonary function tests. After excluding all known
causes of ILD, IPF was diagnosed based on clinical and radiographic criteria, and when
necessary, on surgical lung biopsies, followed by multi-disciplinary discussion (Flaherty
et al. 2004; Raghu et al. 2018). The diagnosis of fibrotic ILD other than IPF was based on
clinical presentation, laboratoristic, bronchoscopic, radiographic investigations and, when
indicated (e.g. non-specific interstitial pneumonia cases), surgical lung biopsies. Patient
charts were also reviewed for current medications and results of pulmonary function tests
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and six-minute walk tests. Pulmonary function tests and six-minute walk tests were
performed as part of patients’ standard of care and according to the American Thoracic
Society guidelines (American Thoracic Society (ATS) 2002; Standardization of
Spirometry, 1994 Update. American Thoracic Society. 1995).

4.2.3

Bioelectrical Impedance Analysis: Body Composition

Estimates of fat-free mass index (FFMI) and body-fat mass index (BFMI) were determined
using dual frequency BIA (BodyStat 1500MD, UK). BIA is an easy and convenient bedside
tool validated in a variety of clinical settings (Fuller, Sawyer, and Elia 1994; Ghosh et al.
1997; Steiner et al. 2002) whereby a 50 kHz electrical current is passed through the body
via two electrodes placed on the surfaces of the right hand and foot measured at fixed
frequencies (BodyStat 2017). FFMI and BFMI were calculated using estimates of fat-free
mass and body fat mass obtained using BIA according to the following equations: FFMI=
fat-free mass (kg) / [height (m)]2, and BFMI= body fat mass (kg) / [height (m)]2,
respectively. FFMI and BFMI are affected by factors such as sex and age, therefore, FFMI
and BFMI z-scores (z-FFMI and z-BFMI) were calculated to account for these factors
based on population norms (Kyle et al. 2001). A z-score of zero indicates a value equal to
the population mean of healthy subjects, a positive z-score indicates a value is greater than
the population mean, and a negative z-score indicates a value less than the population
mean. z-FFMI and z-BFMI were calculated according to the following equation: z-score =
(x - xpopulation mean)/ standard deviationpopulation (SD).

4.2.4

Nutrition Assessment

The gold standard of nutrition assessment is the SGA. The SGA collectively considers diet
and weight history, disease history as it relates to catabolism, nutrition-related functional
status, gastrointestinal issues, and a physical examination to detect clinical signs of muscle
wasting, subcutaneous fat loss and edema taken all together to determine overall nutrition
status (Detsky et al. 1987). SGA categories, A, B and C, represent well-nourished,
moderate malnutrition or suspected of being malnourished, and severe malnutrition,
respectively. SGA has been validated in a variety of disease states (Baccaro et al. 2007;
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Detsky et al. 1987). SGA was completed according to the method outlined by Detsky et al.
(1987) (Detsky et al. 1987)(Detsky et al. 1987)(Detsky et al. 1987)(Detsky et al.
1987)(Detsky et al. 1987)and was performed by a registered dietitian (SR).

4.2.5

Surrogate Markers of Nutrition Status: Phase Angle
and Impedance Ratio

PhA and IR are raw measures of BIA thought to be surrogate markers of nutrition status in
various clinical populations (Kuchnia et al. 2017; Rinaldi et al. 2019). PhA is related to the
resistance and reactance of a current as it travels through the body at a constant frequency
of 50kHz (PhA = arctan(reactance/resistance)). The IR is the ratio of impedances at 200
kHz and 5 kHz. A lower PhA or an IR closer to 1 indicates poorer cellular health. Age, sex
and BMI can affect raw values of PhA and IR; therefore, to control for these confounding
factors, a standardized phase angle (SPhA) and IR z-score (z-IR) were calculated using
population norms (Bosy-Westphal et al. 2006; Kuchnia et al. 2017) according to the zscore equation noted above.

4.2.6

Statistical Analysis

Quantitative variables are expressed as mean ± standard deviation (SD) and qualitative
variables are displayed as frequencies. The Shapiro-Wilk test was used to determine
normality of variables. To test for significant across groups a one-way ANOVA was used
with parametric data and the Kruskal-Wallis test was used with nonparametric data. To test
for between group significance, the independent samples t-test was used with parametric
data and the Mann-Whitney U test was used with nonparametric data. The Pearson’s
correlation coefficient (r) was used to determine the strength and direction of two
continuous parametric variables, and the Spearman’s rho (rs) was used for comparison of
nonparametric continuous variables or comparison of a continuous and categorical
variable. Correlation coefficients were interpreted as previously suggested (Cohen 1988);
Pearson’s correlation coefficient: r = 0.10-0.29 = a small; r = 030-0.49 = medium; r = 0.501.00 = large; Spearman’s rho,: rs < .16 = too low to be meaningful; rs = 0.16-0.29 = weak
to low; rs = 0.3-0.49 = low to moderate; rs = 0.5-0.69 = moderate; rs = 0.7- 0.89 = strong; rs
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= 0.9-1 = very strong. Stepwise multiple regression analysis selected the independent
contributors of 6MWD. Multinomial logistic regression was used to determine odds ratios
and 95% confidence intervals among factors with SGA groups. P-values <0.05 were
regarded as significant. Statistical analysis was performed with IBM® SPSS® Statistics
Version 26 software package.

Results
Sociodemographic patient characteristics and fibrotic ILD diagnoses are shown in Table
4. Anthropometric and nutrition status data are displayed in Table 5. 43% of participants
were identified as SGA-A (well-nourished), 49% were SGA-B (moderately
malnourished), and the remaining 8% were SGA-C (severely malnourished). Raw values
of PhA and IR were significantly greater and significantly lower in males, respectively.
Mean SPhA was -0.44 ± 1.08 SD, and mean z-IR was 5.73 ± 1.52. 6MWD was not
significantly different between males and females.
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Table 4 Patient characteristics (N=78).
Mean ± SD
or Frequency (%)

Demographics/Clinical Characteristics
Age (years)
Sex
Male
Female

68.4 ± 10.0
38 (48.7)
40 (51.3)

Diagnosis
Idiopathic pulmonary fibrosis
Drug-induced toxicity
Rheumatoid arthritis related ILD
Non-specific interstitial pneumonia
Chronic hypersensitivity pneumonitis
Unclassifiable ILD
Scleroderma-related ILD
Sarcoidosis (stages III-IV)
Vasculitis-related ILD

36 (46.2)
10 (12.8)
8 (10.3)
8 (10.3)
5 (6.4)
4 (5.1)
3 (3.8)
2 (2.6)
2 (2.6)

Medication usage
Proton pump inhibitors
Pirfenidone
N-acetylcysteine
Mycophenolate mofetil
Nintedanib

43 (55.1)
16 (20.5)
12 (15.4)
9 (11.5)
2 (2.6)

Pulmonary Function and Exercise Capacity
FEV1 (% predicted)
FVC (% predicted)
DLCO (% predicted)
6MWD (m)
Male
Female

75.1 ± 18.9
71.2 ± 19.5
40.6 ± 17.1
335.6 ± 109.8
335.4 ± 120.2
335.8 ± 100.5

Continuous variables are expressed as mean ± standard
deviation. ILD, interstitial lung disease; FEV, forced expiratory
volume; FVC, forced vital capacity; DLCO, diffusing capacity
for carbon monoxide; 6MWD, six-minute walk distance.
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Table 5 Anthropometric and nutrition data (N=78).

Clinical Characteristics

Mean ± SD
or Frequency (%)

Anthropometry
BMI (kg/m2)
z-FFMI (SD)
z-BFMI (SD)

30.8 ± 7.3
0.39 ± 1.98
2.27 ± 2.15

Nutritional Indices
SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)
Phase angle (°) (n=77)
Male
Female
Standardized phase angle (SD)
Impedance ratio (n=65)
Male
Female
Impedance ratio z-score (SD)

34 (43.6)
38 (48.7)
6 (7.7)
5.55 ± 1.15⸹
4.90 ± 0.81
-0.44 ± 1.08
0.881 ± 0.813†
0.899 ± 0.028
5.73 ± 1.52

Continuous variables are expressed as mean ± standard
deviation. BMI, body mass index; SD, standard deviation;
SGA, subjective global assessment; z-BFMI, body-fat mass
index z-score; z-FFMI, fat-free mass index z-score.
⸹ Significant difference between sexes of p<0.01.
† Significant difference between sexes of p=0.02.

Results of the bivariate correlation analysis are shown in Table 6. The relationship
between age, z-FFMI, %FVC and SGA with 6MWD was statistically significant
(p<0.05). The relationships between 6MWD and sex, BMI, and z-BFMI were not
statistically significant. Variables significantly correlated with 6MWD were then tested
together in a stepwise regression analysis displayed in Table 7. As SGA accounts for loss
of fat-free mass in its assessment, z-FFMI and SGA were analyzed in separate models.
When controlling for lung function using %FVC, z-FFMI (β=15.68, p=0.02) and SGA
(β=-67.82, p=0.01) were still significant independent predictors of exercise capacity
(Table 7).
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Table 6 Relationship between physiological, clinical variables and 6-minute walk
distance.
Variable
Age
%FVC
BMI
z-FFMI
Sex
z-BFMI
SGA

r
0.31
0.30
0.03
0.28
rs
-0.04
0.00
-0.38

p-value
0.01
0.01
0.79
0.02
p-value
0.74
0.99
<0.01

BMI, body mass index; %FVC, percent
predicted forced vital capacity; r,
Pearson’s correlation coefficient; rs,
Spearman’s rho; SGA, subjective global
assessment; z-BFMI, body-fat mass
index z-score; z-FFMI, fat-free mass
index z-score.
Table 7 Linear regression: predictors of 6-minute walk distance.
Model
1
Model
2

Variables
%FVC
z-FFMI
%FVC
SGA

r

R2

0.42

0.17

0.49

0.24

B
1.67
15.68
1.71
-67.82

β
0.29
0.29
0.30
-0.39

95% CI
0.36-2.98
3.18-28.18
0.46-2.97
-106.09-(-29.54)

p-value
0.01
0.02
<0.01
<0.01

B; unstandardized beta coefficient; β, standardized beta coefficient; %FVC, percent
predicted forced vital capacity; r, Pearson’s correlation coefficient; SGA, subjective
global assessment, z-FFMI, fat-free mass index z-score.
Mean SPhA was not significantly different across SGA groups; however, mean z-IR was
significantly greater in the SGA-C group versus the SGA-A (p<0.01) and SGA-B
(p=0.04) groups (Table 5). No variables significantly affected the odds of moderate
malnutrition (SGA-B) compared to the well-nourished group (SGA-A) (Table 6).
However, increased age [OR 1.10, 95% CI (1.01-1.25), p=0.04] and z-IR [OR 2.76, 95%
CI (1.27-6.03), p=0.02] had increased odds of severe malnutrition (SGA-C) as compared
to the well-nourished group (SGA-A). Increased z-FFMI [OR 0.34, 95% CI (0.17-0.68),
p=0.03], z-BFMI (OR 0.39, 95% CI (0.17-0.91), p=0.03) and BMI [OR 0.73, 95% CI
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(0.57-0.92), p=0.01] had decreased odds of severe malnutrition (SGA-C) as compared to
the well-nourished group (SGA-A).
Table 8 Mean SPhA and z-IR across SGA categories
SGA Category
SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)

SPha (SD)
-0.07 ± 0.92
-0.78 ± 1.14
-0.70 ± 1.21

z-IR (SD)⸹
5.39 ± 1.34†
5.77 ± 1.55‡
7.40 ± 1.51

A one-way ANOVA was used to compare means across groups. An independent sample
t-test was used to compare between 2 groups. SD, standard deviation; SGA, subjective
global assessment; SPhA, standardized phase angle; z-IR, impedance ratio z-score.
⸹p=0.02 across groups
†
p<0.01 between SGA-A vs SGA-C
‡p=0.04 between SGA-B and SGA-C

Table 9 Multinomial logistic regression using SGA-A (well-nourished) as the reference
category.
Variables

R2

Age
%FVC
BMI
z-FFMI
z-BFMI
SPhA
z-IR

0.08
0.00
0.18
0.21
0.12
0.05
0.14

SGA-A (wellnourished)
OR (95% CI)
1
1
1
1
1
1
1

SGA-B (moderate
malnutrition)
OR (95% CI) p-value
1.03 (0.98-1.08) 0.27
1.00 (0.98-1.03) 0.79
0.97 (0.91-1.04) 0.41
0.80 (0.62-1.05) 0.11
0.91 (0.73-1.14) 0.41
0.68 (0.44-1.07) 0.10
1.21 (0.84-1.73) 0.32

SGA-C (severe
malnutrition)
OR (95% CI) p-value
1.10 (1.01-1.25) 0.04
1.00 (0.96-1.05) 0.98
0.73 (0.57-0.92) 0.01
0.34 (0.17-0.68) <0.01
0.39 (0.17-0.91) 0.03
0.60 (0.26-1.42) 0.25
2.76 (1.27-6.03) 0.02

BMI, body mass index; CI, confidence interval; OR, odds ratio; %FVC, percent
predicted forced vital capacity; R2, Nagelkerke’s R squared; SPhA, standardized phase
angle; z-BFMI, body fat mass index z-score; z-FFMI, fat-free mass index z-score; z-IR,
impedance ratio z-score.
Due to limited numbers in the SGA-C group, we were not able to test for association
between nutrition status and medication use across all three SGA categories. Between
well-nourished (SGA-A) and malnourished groups combined (SGA-B+C), no significant
associations with medication use were found (data not shown). Additionally, z-FFMI was
not significantly different between type of ILD medication groups (data not shown).
Similarly, with limited numbers across diagnoses we were not able to test for significant
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associations between nutrition status and diagnosis. However, of note, all 6 participants
with severe malnutrition (SGA-C) had IPF.

Discussion
This study examined the influence of body composition and nutrition status on exercise
capacity in a cohort of patients with fibrotic ILDs. z-FFMI had a small relationship (r=0.28)
with exercise capacity and was a significant predictor of exercise capacity when controlled
for lung function. Worsened nutrition status had a low to moderate relationship (r=-0.38)
with exercise capacity and was significantly associated with decreased exercise capacity
independent of lung function.
Muscle dysfunction may be worsened by factors such as age, inactivity and medication
side effects (Nakazawa, Cox, and Holland 2017). In various ILDs, characteristics
suggestive of muscle dysfunction related to inactivity or disuse have been observed. In a
study of individuals with advanced ILD listed for lung transplant, muscle atrophy and
weakness were seen in greater amounts in lower limb muscles of the quadriceps compared
with upper limb muscles of the biceps (Mendes et al. 2015). Similarly, in fibrotic idiopathic
interstitial pneumonias, quadricep muscle strength and endurance was significantly lower
when compared to healthy controls (Mendoza et al. 2014). Interestingly, quadriceps muscle
strength (r=0.44, p=0.03), but not total fat-free mass (r=-0.05, p=0.78), was shown to be a
significantly correlated with 6MWD in the healthy controls (Mendoza et al. 2014). We
demonstrated that z-FFMI, which controlled fat-free mass for height, age and sex, was
significantly associated with exercise capacity independent of lung function. This is in line
with previous data which suggests that muscle dysfunction as a result of disuse, or loss of
muscle mass is indicative of exercise capacity (Holland et al. 2008; Raghu et al. 2011).
Our results demonstrated a positive relationship between exercise capacity and nutrition.
However, the influence of poor nutrition status on exercise capacity has not been well
explored in ILD patients. In other chronic lung diseases, such as COPD, there appears to
be a nutritional influence on exercise capacity. Specifically, normal versus low 6MWD
was associated with lower odds of malnutrition assessed using the Mini Nutrition
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Assessment® [OR 0.835 95% CI (0.735-0.908), p=0.005] in a group of COPD patients
(Matkovic et al. 2017). Additionally, worsened nutrition status assessed using Mini
Nutrition Assessment® was associated with worse dyspnea scores [OR 22.888, 95% CI
(2.103-249.065), p=0.01], and lung function (FEV1/FVC ratio) [OR 0.898, 95% CI
(0.826-0.977), p=0.012] (Mete et al. 2018). In ILD, nutrition support is included as a nonexercise component in pulmonary rehabilitation programs (Nakazawa, Cox, and Holland
2017). Specific nutrition recommendations, however, are limited in best practice
guidelines (Raghu et al. 2011; Travis et al. 2013), and to the best of our knowledge, no
studies have thoroughly explored the influence of poor nutrition status on diminished
exercise capacity in ILD patients. Our results demonstrated a positive relationship
between exercise capacity and nutrition status independent of lung function. With each
SGA nutrition category improvement, we would expect 6MWD to increase by an average
of 67.8 metres (β=-67.8). These promising results support the theory that nutritional
rehabilitation as part of ILD care has the potential to improve functional exercise
capacity.
Few studies have assessed the prevalence of malnutrition in ILD. The majority of
nutrition-related research in ILD has related to weight, BMI (Nishiyama et al. 2017) and
FFMI (Nishiyama et al. 2017); however, no studies have assessed overall nutrition status
comprehensively (Rinaldi, Mura, and Madill 2017). In this study, nutrition status was
comprehensively assessed using the gold standard for nutrition assessment, SGA, which
considers weight change, disease history, gastrointestinal and medication-related side
effects and clinical characteristics such as edema, muscle wasting and fat loss (Detsky et
al. 1987). We found that the majority of fibrotic ILD patients, according to SGA, were
malnourished. Specifically, 49% of participants were moderately malnourished, and 8%
were severely malnourished. Additionally, we found that increased age and various
anthropometric measures such as BMI, z-FFMI and z-BFMI were associated with risk of
severe malnutrition. As SGA captures factors such as weight loss, and signs of muscle
wasting and subcutaneous fat loss using a clinical assessment, it is not surprising that
greater values of BMI, and lean body mass and body fat were associated with lower odds
of severe malnutrition. Interestingly, lung function assessed using %FVC was not
associated with moderate nor severe malnutrition.
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Trained clinicians, such as dietitians, needed to perform the SGA may not be readily
available as part of standard care, therefore surrogate markers of nutrition, such as PhA
and IR, have been suggested in a number of different disease states (Kuchnia et al. 2017;
Kyle et al. 2012; Kyle, Genton, and Pichard 2013; Malecka-Massalska et al. 2016; Ott et
al. 1995; Plank and Li 2013). No studies to date have explored the relationship between
PhA nor IR in ILD. In this study, we did not observe any significant differences in mean
SPhA between SGA groups. However, a greater z-IR, which indicates poorer cellular
health, had significantly increased odds of severe malnutrition as compared to the wellnourished group. This is in line with previous research that suggests PhA may not be an
appropriate standalone measure of nutrition (Rinaldi et al. 2019) and that IR may be a
more robust measure of nutrition than PhA (Castillo Martinez et al. 2007; Plank and Li
2013).
Our study has some limitations. For example, the moderate sample size (N=78) limited
our ability to assess the influence of specific diagnosis or medication use on nutrition
status. Common ILD medications are known to have nutrition-related side effects. For
example, anti-fibrotic agents are commonly associated with decreased appetite, nausea
and diarrhea which would very likely affect an individual’s ability to maintain good
nutrition. Therefore, further research is needed to thoroughly explore the risk of
malnutrition with specific medication use and between ILD subtypes. Additionally, we
acknowledge that ILD patients are a heterogeneous group, however, our study population
included only fibrotic-ILDs which aimed to limit diagnosis-specific differences among
our participants. As this study was cross-sectional, we were not able to control for recent
changes in disease severity. As such, future research should assess 6-month or 1-year
changes in %FVC (Fernández Fabrellas et al. 2018) to control for worsening, stable or
improved disease states. There is limited knowledge about the relationship of nutritional
status on the clinical course of ILD, a potentially important implication on the outcome
and quality of life of these patients. This research provides justification for the need of
nutrition professionals in the standard of care of ILD patients. Future research should
explore nutrition interventions, for example, aimed at improving lean body mass, and
assess how improving nutrition can affect functional exercise capacity in patients with
ILD.
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Conclusion
Decreased FFMI controlled for age and sex and severe malnutrition independent of lung
function were significantly associated with exercise capacity in fibrotic ILD. SPhA was
not significantly different between SGA groups, however, z-IR was significantly greater
in the SGA-C (severe malnutrition) versus SGA-A (well-nourished) groups indicating
worsened cell health in severe malnutrition.
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Chapter 5
5

Fat-free mass index controlled for age and sex, and
malnutrition are predictors of survival in interstitial lung
disease.
Abstract

Background: Literature focusing on nutritional variables and survival in interstitial lung
disease (ILD) is limited by its focus on weight and body mass index (BMI) and has not
considered body composition. Objectives: The primary objective of this study was to
examine whether body composition measures, specifically fat-free mass index z-score (zFFMI) and body fat mass index z-score (z-BFMI), were predictors of survival in ILD
patients. The second objective was to examine if nutrition status was a predictor of survival.
Method: 78 outpatients diagnosed with fibrotic ILD were recruited in this cross-sectional
study. Body composition data using dual frequency bioelectrical impedance analysis
(BodyStat 1500MD, UK), and nutrition status was determined using the subjective global
assessment (SGA). To control for age and sex, z-FFMI and z-BFMI were calculated using
population means. Participant charts were reviewed for diagnosis age, disease severity and
exercise capacity. Results: Age [HR 1.08, 95% CI (1.03-1.13), p<0.01], BMI [HR 0.90,
95% CI (0.84-0.97), p<0.01)], z-FFMI [HR 0.70, 95% CI (0.56-0.87), p=0.02], z-BFMI
[HR 0.74, 95% CI (0.57-0.96), p<0.01], six-minute walk distance (6MWD) [HR 0.99, 95%
CI (0.99-1.00), p<0.01], % predicted diffusing capacity for carbon monoxide (%DLco)
[HR 0.93, 95% CI (0.89-0.97), p<0.01] and severe malnutrition (SGA-C) [HR 6.98, 95%
CI (2.00-24.27), p<0.01] were significant predictors of survival. When controlled for
exercise capacity and disease severity, z-FFMI and severe malnutrition were significant
predictors of survival independent of %DLco. Conclusion: z-FFMI and severe malnutrition
were significant predictors of survival in fibrotic ILD patients independent of disease
severity.

72

Introduction
Interstitial lung disease (ILD) is a group of disorders that involve disruption of the distal
lung parenchyma, with various degrees of inflammation and/or fibrosis. A common form
of ILD is idiopathic pulmonary fibrosis (IPF) and is characterized by progressive scaring
of the lung parenchyma, with minimal inflammation. IPF is relentlessly progressive, with
a dismal prognosis of 2-5 years, in the absence of treatment (Raghu et al. 2011). Clinical
markers such as lung function, 6-minute walk distance (6MWD), dyspnea scores and
body mass index (BMI) are reliable predictors of survival in ILD (Alakhras et al. 2007;
Collard et al. 2003; Manali et al. 2008). To date, research examining the relationship
between nutritional factors and survival in ILD is limited by its focus on weight and BMI
and has not fully addressed the influence of body composition and overall nutrition status
on survival.
Low fat-free mass index (FFMI), fat-free mass standardized for height, has been shown to
be a predictor of mortality in various disease states (Chang et al. 2019; Schols et al. 2005).
In IPF, Nishiyama et al. (2017) found that FFMI, but not BMI, was a significant predictor
of survival. Age, sex and height are core biological factors affecting fat-free mass, but it
may also be affected by environmental factors such as physical activity and protein intake.
Therefore, the calculation of a FFMI z-score (z-FFMI) aims to account for some of these
confounding factors by generating a value indicating how far away an individual’s measure
is from the mean of healthy population reference values. Similarly, this can be used to
calculate body fat mass index z-scores (z-BFMI).
In other chronic lung diseases, a significant portion of patients have been identified as
malnourished (Günay et al. 2013; Gupta, Kant, and Mishra 2010). In ILD, the prevalence
of malnutrition is not well established. The gold standard of nutrition assessment is the
subjective global assessment (SGA) which has been validated in a variety of disease states
(Baccaro et al. 2007; Detsky et al. 1987). SGA considers diet, weight history, functional
status, gastrointestinal issues, and disease history, combined with a physical examination
to identify signs of muscle wasting, subcutaneous fat loss, and edema, taken together to
determine nutritional status.
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The primary objective of this study was to examine whether measures of body composition,
specifically z-FFMI and z-BFMI, are independent predictors of survival in ILD patients.
The second objective was to determine the prevalence of malnutrition using SGA and
examine if nutrition status is a predictor of survival.

Methods
5.3.1

Study Population

In this cross-sectional study, 78 patients diagnosed with fibrotic ILD were recruited from
an outpatient ILD clinic. Inclusion criteria included ambulatory patients over 18 years of
age with diagnosis of a fibrotic ILD. Patients were excluded according to the following
criteria: inability to provide consent due to communication issues (cognitive and motor),
presence of cardiac implantable electrical devices, non-stable ILD patients defined as those
with infections and/or fever, admitted to hospital in the previous month, or presence of an
unstable co-morbid illness. The study protocol was approved by the Western University
Research Ethics Board (protocol n. 104028 and 103186).

5.3.2

Diagnosis, Disease Severity and 6-Minute Walk Test

The presence of fibrotic ILD was defined based on high-resolution chest computed
tomography scan and compatible pulmonary function tests. After excluding all known
causes of ILD, IPF was diagnosed based on clinical and radiographic criteria, and when
necessary, on surgical lung biopsies, followed by multi-disciplinary discussion (Flaherty
et al. 2004; Raghu et al. 2018). The diagnosis of fibrotic ILD other than IPF was based on
clinical presentation, laboratoristic, bronchoscopic, radiographic investigations, and when
indicated (e.g. non-specific interstitial pneumonia cases), surgical lung biopsies. Patients
with combined pulmonary fibrosis and emphysema (CPFE) were also excluded from the
study, and coexisting emphysema was always minimal (≤5% of total lung volume). Patient
charts were also reviewed for current medications and results of pulmonary function tests
and six-minute walk tests. Pulmonary function tests and six-minute walk tests were
performed as part of patients’ standard of care and according to the American Thoracic
Society guidelines (American Thoracic Society (ATS) 2002; Standardization of
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Spirometry, 1994 Update. American Thoracic Society. 1995). Time from diagnosis was
calculated from date ILD was diagnosed to study recruitment date.

5.3.3

Body Composition Assessment

Body composition data were obtained using dual frequency bioelectrical impedance
analysis (BIA) (BodyStat 1500MD, UK). BIA is an easy and convenient bedside tool that
is validated in a variety of clinical settings (Fuller, Sawyer, and Elia 1994; Ghosh et al.
1997; Steiner et al. 2002). Participants were asked to rest supine on a bed in the clinic while
breathing normally. Resistance and reactance were measured via passing a 50 kHz
electrical current through the body via two electrodes placed on the surfaces of the right
hand and foot while measuring the impedance at fixed frequencies (BodyStat 2017). FFMI
and BFMI were calculated using estimates of fat-free mass and body fat mass obtained
using BIA according to the following equations: FFMI= fat-free mass (kg) / [height (m)]2,
and BFMI= body fat mass (kg) / [height (m)]2, respectively. z-FFMI and z-BFMI were then
calculated using population means by age and sex groups (Kyle et al. 2001) according to
the following equation: z-score = (x - xpopulation mean)/ standard deviationpopulation (SD). FFMI
and BFMI cut-offs suggested by Kyle et al. (2001) were used to classify patients into the
following categories: normal (normal FFMI and BFMI), sarcopenia (low FFMI and normal
BFMI), obesity (normal FFMI and high BFMI), and sarcopenic obesity (low FFMI and
high BFMI) (Kyle et al. 2005).

5.3.4

Nutrition Assessment

SGA was completed according to the method outlined by Detsky et al (1987) and was
completed by a registered dietitian (SR). SGA is considered the gold standard method to
identify malnutrition combining dietary, weight, functional, gastrointestinal and disease
history with a physical examination to arrive at a categorical ranking. Categories A, B
and C represent well-nourished, moderate malnutrition or suspected of being
malnourished, and severe malnutrition, respectively.
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Outcome

5.3.5

The primary outcome measure was 2-year lung transplant-free survival. The survival of
patients was assessed starting from the time of their BIA assessment up to 2 years following
this date.

Statistical Analysis

5.3.6

Descriptive statistics were evaluated; continuous variables are expressed as mean ±
standard deviation (SD) and categorical variables are displayed as frequencies. An
independent samples t-test was used to compare differences in means between sexes. Cox
proportional hazard regression models were performed to identify significant predictors of
survival. Receiver operator characteristic (ROC) analyses were used to determine the best
cut point of a variable towards the endpoint, by examining accuracy of predicting endpoints
(sum of sensitivity and specificity). Lung transplant-free survival was evaluated using
Kaplan-Meier curves and the log rank test. P-values <0.05 were regarded as significant.
Statistical analysis was performed with IBM® SPSS® Statistics Version 26 software
package.

Results
Patient characteristics including diagnosis, clinical characteristics, body composition and
nutrition status are shown in Table 10. Mean age was 68.4±10.0 years. 51.3% of
participants were female. Mean BMI was 30.8±7.3 kg/m2. As expected, FFMI was
significantly greater in males versus females (p<0.001), and BFMI was significantly lower
in males versus females (p<0.001). Mean z-FFMI and z-BFMI, standardized for age and
sex population norms (Kyle et al. 2001), were 0.39±1.98 SD and 2.27±2.15 SD,
respectively. Most patients were diagnosed with moderate malnutrition (49%). 60.3% of
participants were classified as obese, while 11.5% had a normal body composition, 20.5%
had sarcopenia and 7.7% were sarcopenic obese. Mean observation time was 19.4±7.3
months. At the end of the 2-year observation period, 26% (n=20) of participants had passed
or were transplanted.
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Table 10 Patient demographics (N=78).
Clinical Characteristics
Age (years)
Sex
Male
Female
Diagnosis
Idiopathic pulmonary fibrosis
Drug-induced toxicity
Rheumatoid arthritis related ILD
Non-specific interstitial pneumonia
Chronic hypersensitivity pneumonitis
Unclassifiable ILD
Scleroderma-related ILD
Vasculitis-related ILD
Sarcoidosis (stages III-IV)

Mean ± SD
or Frequency (%)
68.4 ± 10.0
38 (48.7)
40 (51.3)

36 (46.2)
10 (12.8)
8 (10.3)
8 (10.3)
5 (6.4)
4 (5.1)
3 (3.8)
2 (2.6)
2 (2.6)

Years from diagnosis [median (range)] 1 (0-13)
ILD Medications
Proton pump inhibitors
Oxygen supplementation
Pirfenidone
N-acetylcysteine
Nintedanib

43 (55.1)
24 (30.8)
16 (20.5)
12 (15.4)
2 (2.6)

Anthropometry and Nutritional Indices
BMI (kg/m2)
FFMI (kg/m2)
male
female
BFMI (kg/m2)
male
female
FFMI z-score (SD)
BFMI z-score (SD)

30.8 ± 7.3
18.2 ± 3.6*
20.0 ± 3.6
16.4 ± 2.7
12.6 ± 5.5*
9.9 ± 3.8
15.2 ± 5.7
0.39 ± 1.98
2.27 ± 2.15

Body Composition
Normal
Sarcopenia
Obesity
Sarcopenic Obesity

9 (11.5)
16 (20.5)
47 (60.3)
6 (7.7)

Nutrition Status [n (%)]
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SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)

34 (43.6)
38 (48.7)
6 (7.7)

Pulmonary Function and Exercise Capacity
FEV1 (% predicted)
75.1 ± 18.9
FVC (% predicted)
71.1 ± 19.5
DLCO (% predicted)
40.6 ± 17.1
6MWD (m)
335.6 ± 109.8
6MWD (% predicted)
74.4 ± 22.9
Continuous variables are expressed as mean ± standard
deviation. BFMI, body-fat mass index; BMI, body mass
index; FFMI, fat-free mass index; IPF, idiopathic
pulmonary fibrosis; ILD, interstitial lung disease; SD,
standard deviation; SGA, subjective global assessment;
6MWD, six-minute walk distance; %DLCO, percent
predicted diffusing capacity for carbon monoxide; %FEV,
percent predicted forced expiratory volume; %FVC,
percent predicted forced vital capacity.
* independent samples t-test indicated significant
difference (p<0.001) between sexes
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The results of the univariate Cox proportional hazard model are summarized in Table 11.
Age was not included in the models as z-FFMI, z-BFMI and %DLco values control for
differences in age. z-FFMI and SGA were not included in the same model as a component
of SGA includes assessment of loss of fat-free mass. The results of the multiple Cox
proportional hazard models are shown in Table 12. z-FFMI was a significant predictor of
survival independent of z-BFMI and %DLco but not 6MWD (Models 1-3, Table 12).
SGA-C (severe malnutrition) as compared to SGA-A (well-nourished) was a significant
predictor of survival independent of %DLco but not 6MWD (Models 4-5, Table 12).
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Table 11 Univariate Cox proportional analysis.
Variable

HR

95% CI

p-value

Sex
Age
Time from diagnosis

1.76
1.08
1.00

(0.72-4.32)
(1.03-1.13)
(0.85-1.17)

0.22
<0.01
0.96

Prednisone
Pirfenidone
N-acetylcysteine
Supplemental oxygen
MMF

0.75
1.91
3.17
1.76
0.04

(0.29-1.95)
(0.73-4.98)
(1.21-8.28)
(0.72-4.31)
(0.00-10.03)

0.56
0.19
0.02
0.22
0.25

%FEV1
%FVC
%DLCO

0.99
0.99
0.93

(0.97-1.02)
(0.97-1.01)
(0.89-0.97)

0.51
0.36
<0.01

BMI
z-FFMI
z-BFMI
6MWD

0.90
0.70
0.74
0.99

(0.84-0.97)
(0.56-0.87)
(0.57-0.96)
(0.99-1.00)

<0.01
<0.01
0.02
<0.01

SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)

1
2.04
6.98

--(0.70-5.96)
(2.00-24.27)

--0.20
<0.01

Normal
Sarcopenia
Obesity
Sarcopenic Obesity

1
5.49
1.66
5.61

---(0.69-43.97)
(0.21-13.28)
(0.58-54.06)

--0.11
0.63
0.14

Obesity
Sarcopenic Obesity

1
3.23

---(0.85-12.21)

--0.08

BMI, body mass index; CI, confidence interval; HR, hazard ratio; SGA, subjective
global assessment; z-BFMI, body-fat mass index z-score; z-FFMI, fat-free mass
index z-score; 6MWD, six-minute walk distance; %DLCO, percent predicted
diffusing capacity for carbon monoxide; %FEV1, percent predicted forced
expiratory volume; %FVC, percent predicted forced vital capacity.
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Table 12 Cox regression analyses to identify independent predictors of lung transplantfree survival.
Variables

HR

95% CI

p-value

Model 1
z-FFMI (SD)
z-BFMI (SD)

0.72
0.78

(0.53-0.98)
(0.69-1.32)

0.03
0.78

%DLCO

0.67
0.92

(0.51-0.86)
(0.88-0.97)

<0.01
<0.01

Model 3
z-FFMI (SD)
6MWD (m)

0.82
0.99

(0.65-1.03)
(0.99-1.00)

0.09
<0.01

Model 4
SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)
%DLco

1
2.06
7.24
0.93

-----(0.56-7.63)
(1.68-31.15)
(0.89-0.97)

----0.28
<0.01
<0.01

Model 5
SGA-A (well-nourished)
SGA-B (moderate malnutrition)
SGA-C (severe malnutrition)
6MWD (m)

1
1.42
3.13
0.99

---(0.47-4.26)
(0.75-13.01)
(0.99-1.00)

---0.54
0.12
<0.01

Model 2
z-FFMI (SD)

CI, confidence interval; HR, hazard ratio; SD, standard deviation; SGA,
subjective global assessment; z-FFMI, fat-free mass index z-score; z-BFMI,
body-fat mass index z-score; 6MWD, six-minute walk distance; %DLCO,
percent predicted diffusing capacity for carbon monoxide.

Results of ROC analysis for z-FFMI is displayed in Table 13. The ideal z-FFMI cut-off
was <0.37 SD with 62.1% sensitivity and 80.0% specificity. Kaplan-Meier survival curves
using the ideal cut-offs determined using ROC analysis for z-FFMI is shown in Figure 4.
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Table 13 Results of receiver operator characteristic analysis

z-FFMI

AUC (95% CI)

p-value

Cut-off (SD)

0.74 (0.62-0.87)

<0.01

0.37

Sensitivity Specificity
(%)
(%)
62.1

80.0

AUC, area under the curve; CI, confidence interval; SD, standard deviation; zFFMI, fat-free mass index z-score.

Figure 4 Kaplan–Meier survival curve using ideal cut-off for fat-free mass index z-score
(z-FFMI) (p=0.001). The solid line represents z-FFMI ≥ 0.37 SD and the dotted line
represents z-FFMI <0.37 SD. Survival curves was compared using log-rank statistics
(• represent censored cases).
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Discussion
This study examined the influence of body composition parameters, z-FFMI and z-BFMI,
and nutrition status on survival in a group of fibrotic ILD patients. z-FFMI, z-BFMI and
severe malnutrition (SGA-C) were shown to be significant predictors of survival in ILD.
However, when controlled for disease severity only z-FFMI and severe malnutrition were
independent predictors of survival in ILD patients.
In our univariate analysis BMI was found to be a significant predictor of survival in ILD
patients. Research focusing on BMI and survival in IPF patients has demonstrated a
paradoxical effect of obesity on survival, in that, an increased BMI acts as a protective
factor on mortality. In a study by Alakhras et al. (2007), individuals with BMIs in the obese
category (>30kg/m2) were shown to have significantly greater survival times than those
with BMIs in the overweight category (25-30kg/m2) and normal category (<25kg/m2).
Similarly, Mura et al. (2012) reported that for every 1-unit increase in BMI there was a
11% lower risk of death at 3-year follow-up in IPF patients (HR 0.89, 95% CI (0.80–0.98),
p=0.0165). Adding to these results, progressive weight loss greater than 5% of total body
weight in 1 year has also been found to be an independent predictor of decreased survival
in IPF (Nakatsuka et al. 2018). Limited studies exist showing the relationship between
increased BMI and decreased mortality in ILDs other than IPF. One recent study, which
included a diverse group of ILDs including ILD secondary to connective tissue disease,
hypersensitivity pneumonitis, and unclassifiable subtypes found that a loss in BMI greater
than 5% in 1 year was associated with significantly shorter survival times, and there was a
2-fold higher risk of death compared to those with a ≤5% loss in BMI in 1 year (Pugashetti
et al. 2018). These results suggest that excess weight may act as a nutritional reserve in
times of poor intake secondary to harsh side effects of medications, or during acute
exacerbations of the disease. Interestingly, we found that only use of N-acetylcholine, an
ILD medication used for its antioxidant effect (Sun, Liu, and Zhao 2016), was associated
with worsened mortality, but corticosteroids, and other anti-fibrotic and anti-inflammatory
medications were not related to survival.
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A strong relationship exists between decreased FFMI and poor prognosis in other chronic
respiratory diseases such as chronic obstructive pulmonary disease (Gologanu et al. 2014;
Schols et al. 2005; Vestbo et al. 2006); however, fewer studies exist in ILD. We
demonstrated a 30% reduction in risk of death for every 1 SD increase in z-FFMI in our
sample of 78 fibrotic ILD patients. Two recent studies exist examining FFMI and survival
in IPF patients. The first study by Nishiyama et al. (2017) found a 36% lower risk of death
with every 1-unit increase in FFMI (HR 0.64, 95% CI (0.43–0.94), p=0.02) in a group of
Japanese IPF patients. Conversely, in a study of IPF patients by Patel et al. (2018) there
was no significant association between FFMI and all-cause mortality at 1-year. Although
conflicting results, neither study controlled for age or sex when analyzing FFMI. Notably,
despite not controlling for confounding factors, Nishiyama et al. (2017) did demonstrate
FFMI to be a significant predictor of survival in their study. This could be due to a nonsignificant difference in FFMI in males versus females in this sample. Different body
composition norms in Japanese versus Caucasian cohorts such as lower BMI and FFMI
have been demonstrated in previous studies (Jensen et al. 2019). However, between sex
statistics were not reported. Patel et al. (2018) did not adjust for sex differences in their
univariate analysis using FFMI as a continuous variable, however, when FFMI was used
as a categorical variable, sex specific cut-offs were applied (FFMI ≥15 kg/m2 for females
and ≥17 kg/m2 for males). A reference source for these cut-offs was not indicated, however,
it is assumed that these cut-offs are based on the European Society for Parenteral and
Enteral Nutrition diagnostic criteria for malnutrition (Cederholm et al. 2015). Although an
important contributor to survival, cuts-offs derived for identification of malnutrition may
not be sensitive or specific to predicting survival outcomes, thus, influencing these nonsignificant findings. Our study intended to control for patient characteristics such as age
and sex which influence FFMI. Using z-FFMI we were able to include both males and
females together in our analyses, and we were able to control for factors such as age-related
fat-free mass loss which can skew results.
We also addressed the impact of body fat on survival. Interestingly, we found that z-BFMI
was a significant predictor of survival. Although it has been demonstrated that excess
weight can increase the workload of breathing and decrease physical performance (Tynan
and Hasse 2004), our results seem to suggest that greater amounts of body fat may be
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protective on survival. It is very likely that the protective effect of excess body fat on
survival observed in this study is related to the relationship between fat-free mass and body
fat mass, in that, as body fat mass increases, greater amounts of fat-free mass may be
required to support this excess weight. Therefore, FFMI may be maintained through a
weight bearing effect. This is further supported by results of our analysis, in which z-BFMI
was no longer a significant predictor of survival when controlled for z-FFMI. These results
appear to suggest a component of sarcopenic obesity affecting the significance of z-BFMI
as a predictor of survival in the presence of worsened disease status and poor exercise
capacity. Specifically, research has shown that excess body fat mass, especially in the
presence of fat-free mass, can have direct detrimental effects on physical performance
(Joppa et al. 2016), systemic inflammation (Joppa et al. 2016), quality of life (Joppa et al.
2016; Öztürk et al. 2018) and prognosis (Gonzalez et al. 2014). We attempted to determine
the influence of body composition on survival, however, we found no significant difference
in odds of death in those with sarcopenia, obesity, nor sarcopenic obesity versus those with
a normal body composition. Additionally, we assessed the specific difference between the
obese and sarcopenic obese groups, however, there was no significant difference (p=0.085)
in chance of death in sarcopenic obesity versus obesity. However, with only 6 patients
identified as sarcopenic obese, our statistical power was limited.
Prevalence of malnutrition in ILD patients has been understudied, and clinical practice
guidelines for the treatment and management of ILD offer limited guidance related to
nutrition (Raghu et al. 2011, 2018). Of the existing research, malnutrition prevalence varies
greatly, and is often identified by a single measure. Jouneau et al. (2019) found that 28%
of patients were malnourished using fat-free mass, 4% were malnourished using BMI, and
5% were malnourished using mid-arm circumference. A conference abstract by Autore et
al. (2013) reported that 26% of patients were at risk of malnutrition using the Mini
Nutritional Assessment Short Form, a validated screening tool designed for populations
>65 years. In our study, the majority of patients were diagnosed with malnutrition, and
those with severe malnutrition, had a 7-fold increased risk of death compared to wellnourished patients. To the best of our knowledge, this study is the first to use a
comprehensive nutrition assessment tool validated to diagnose malnutrition.
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The modest sample size was a limiting factor of this study. First, we were limited to
including no more than two predictor variables in the multiple Cox regression models
keeping in line with the general recommendation that for every one predictor variable
n=10 outcomes, in this case deaths, are required to reduce the risk of overfitting the
model (Norman 2013). Therefore, we were not able to control for both disease severity
and exercise capacity with body composition parameters and nutrition status in the same
model which may have produced different results. Second, with only 6 participants
identified as sarcopenic obese we were not able to fully address the question of whether
increased body fat is protective in all cases. Similarly, limited numbers in our severe
malnutrition group limited statistical power in our analyses. Our cross-sectional study
only assessed body composition, disease severity and exercise capacity at one time point,
however, monitoring changes over time, such as change in body composition or change
in %FVC, can provide additional insights into their influences on survival. Additionally,
we did not use a cohort of healthy individuals for comparison with our sample. However,
the nature of calculating z-scores of body composition parameters innately compares our
sample to healthy population norms of FFMI and BFMI. Lastly, it would be remiss to not
acknowledge that BIA provides estimations of body composition using prediction
equations. Therefore, our results are limited due to the use of estimates of fat-free mass
and body fat mass rather than actual measurements. However, our results are in-line with
previous research that has shown that adiposity (Alakhras et al. 2007) and low muscle
mass (Mendes et al. 2015) is common in ILD.

Conclusion
These results are sufficiently encouraging to warrant further research into the nutritional
status of ILD patients. Future research should focus on the influence of sarcopenic
obesity on survival, and how nutrition interventions targeted at maintaining or increasing
muscle mass over time can affect survival in ILD patients. Furthermore, assessment of
fat-free mass should be considered alongside or in place of BMI as a nutritional variable
when analyzing survival risk of ILD patients as it can better identify those as risk of
death. Additionally, chest computed tomography scans which are completed as part of
diagnosis and clinical monitoring of ILD should be leveraged to measure body
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composition parameters using a gold standard method. In conclusion, in our sample of 78
fibrotic ILD patients, z-FFMI and severe malnutrition independent of disease severity
were significant predictors of survival in ILD patients.
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Chapter 6
6

Overall Conclusion and Future Directions

The overarching purpose of this dissertation research was to better understand the
nutritional concerns in interstitial lung disease (ILD) patients through investigating the
contributions of body composition and nutrition status on exercise capacity and survival
in patients with ILD. This final chapter will discuss the contributions to research, clinical
implications and recommendations, the challenges and limitations of this thesis research,
future research plans, and end with an overall conclusion.

Research Contributions
This dissertation makes several key contributions to knowledge. Chapter 2 reviewed the
literature on ILD background and nutrition-related knowledge to date in ILD. The key
finding from this literature review was that there are numerous nutrition-related concerns
associated with ILD and its treatment which put patients at nutritional risk. Despite this,
nutrition professionals such as registered dietitians (RDs) may not be part of the standard
ILD health care team. This overlooks an important opportunity to improve quality of life
and survival through supporting patients’ nutritional needs.
Chapter 3 examined the appropriateness of phase angle (PhA) as a nutrition indictor in
various disease states. This study was the first systematic review comparing the
subjective global assessment (SGA) which is the gold standard of nutrition assessment
with bioimpedance PhA. The key finding of this systematic review was that overall
evidence quality received a grade of Low, and that continued research is needed in this
area to validate surrogate markers of nutrition status in a variety of disease states.
The objective of Chapter 4 was to examine the relationship between nutrition status and
body composition with functional exercise capacity, and to determine the appropriateness
of bioimpedance parameters (PhA and impedance ratio (IR)) to identify malnutrition in
ILD patients. The results of Chapter 4 showed that SGA-C (severe malnutrition) and low
fat-free mass index z-score (z-FFMI) were associated with worsened exercise capacity in
patients with fibrotic ILD, and that IR z-score (z-IR), but not standardized PhA (SPhA),
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was associated with severe malnutrition. A research gaps exists in the areas of body
composition, nutrition status and surrogate markers of nutrition in ILD. The results of this
chapter address these research gaps. These finding are important to the body of research
on nutrition status and body composition in ILD as it demonstrates that malnutrition or
loss of fat-free mass can negatively impact a person’s ability to perform their activities of
daily living and therefore affect their quality of life.
The purpose of Chapter 5 was to evaluate body composition measures and nutrition
status as predictors of survival in ILD. The results of Chapter 5 revealed that z-FFMI
and SGA-C (severe malnutrition) are independent predictors of survival in patients with
ILD. The findings in this chapter are important to the research field as it challenges
previous research that has narrowly focused on increased weight as a protective factor in
the survival of ILD patients. Rather, this research indicates that increased fat-free mass is
an important component of body weight which offers a protective effect on survival in
ILD. Also, this research is the first to assess the relationship between nutrition status and
survival. The key finding that severe malnutrition, but not moderate malnutrition, was
associated with decreased survival in ILD adds to the ILD knowledge base and warrants
further research exploration.

Clinical Implications
This research provides justification for the need of nutrition professionals as part of a
holistic approach in the care of ILD patients. Previous research has identified patient
education, symptom relief and management of comorbidities as vital components of
supportive care in ILD management (Quinn, Wisse, and Manns 2019). RDs can support
patients in each of these three supportive care components using their nutrition expertise
and skills.
ILD medications are commonly associated with adverse events such as decreased
appetite, nausea or diarrhea, which put patients at nutritional risk. For example, diarrhea
is a common adverse event of the medication Nintedanib (OFEV®), and many patients
may discontinue its use due to this side effect (Galli et al. 2017). Specific nutrition
counselling and patient education on bowel management has the potential to reduce
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bowel frequency as well as prevent additional complications such as dehydration and
malabsorption. Additionally, RDs can support patients to correct or prevent malnutrition.
For example, decreased intake and/or increased energy requirements related to the
increased work of breathing can result in loss of fat-free mass and malnutrition.
RDs can address and educate patients on the conflicting weight-related research in ILD.
For instance, as thoroughly discussed in Chapter 2, an increased body mass index (BMI)
is associated with decreased mortality in ILD patients (Alakhras et al. 2007; Mura et al.
2012), however, this conflicts with both general health weight recommendations and
BMI cut-offs required for lung transplantation. Dietetics is an evidenced-based
profession; therefore, RDs can address nutrition misconceptions and misunderstandings
and provide credible, evidence-based information to ILD patients. RDs can help patients
establish and maintain their own individualized weight and body composition targets.
RDs are qualified to identify indictors of muscle or body fat loss and therefore assess for
risk of sarcopenia and sarcopenic obesity. Therefore, RDs should be included in standard
ILD care in order to establish targetable nutrition care plans for common nutrition
problems thereby improving symptom management and quality of life.

Reflections on Research Challenges
Although the research process can provide a great deal of gratification it also can bring
about challenges. A main difficulty I encountered with this dissertation research was
related to recruitment and timing. Participant recruitment in a relatively rare and
specialized disease can be difficult. In my case, I was fortunate to be working in the ILD
clinic serving southwestern Ontario. However, this meant that patients were frequently
travelling from out of town for their clinic visit with their respirologist, and for some, this
also meant that they were not willing to stay the extra time required for the data
collection required for this study. Furthermore, being a specialized clinic, it only occurred
on one half day per week. Therefore, there were only a limited number of participants
available to recruit each week.
A large challenge was our recruitment capacity at each clinic, specifically related to
limited clinic space to see patients, having only one bioelectrical impedance analysis
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(BIA) device (BodyStat® 1500MDD) for data collection and having only one RD
available to complete the SGA. For example, if all scheduled clinic patients were to
consent to this research study, our capacity as a research team (myself, the RD required
for specific data collection and a variable number of student volunteers each week) would
only be able to collect data on 4-5 participants per clinic at a maximum. As well, patient
clinic visits were generally scheduled 4-6 months apart which meant that if a patient was
interested in participating in the research study, but was not able to be seen on that day
due to time restraints, the research team would possibly have to wait another 4-6 months
to see that patient again. Lastly, with respect to our survival research, our study timeline
was lengthened to allow for a 2-year survival time. Therefore, in preparation for this
dissertation research we were required to limit our cohort to N=78 participants in order to
have the necessary survival data for our analyses.

Limitations
The main limitation of this research was sample size. Our sample size of n=78 in both
studies limited our ability to assess the influence of specific diagnoses, medication use
and body composition categories, such as sarcopenic obesity, in our analyses.
Specifically, we have limited statistical power to assess the influence of sarcopenic
obesity (n=6) on survival. As a result, we were not able to fully address the question of
whether increased body fat mass was protective in all cases. Similarly, although we
reported significance in our analyses of the SGA-C (severe malnutrition) group in its
association with exercise capacity and survival, SGA-C (severe malnutrition) was no
longer a significant predictor of survival when controlled for exercise capacity. As well,
we found no significant difference in SPhA across SGA groups. Therefore, without
greater sample size, we could not say with certainty if there is truly no relationship or if
these non-significant results were due to limited statistical power.
In our survival analyses in Chapter 5, we were limited to including no more than two
predictor variables in the multiple Cox regression models keeping in line with the general
recommendation that n=10 outcomes, in this case deaths, are required for every one
predictor variable to reduce the risk of overfitting the model (Norman 2013). Therefore,
we were not able to control for both disease severity and exercise capacity with body
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composition parameters and nutrition status within the same model which may have
produced different results.
Another limitation of this study is that it is cross-sectional in nature and only assessed
body composition, lung function and exercise capacity at only one time-point; however,
monitoring changes over time, such as change in body composition or change in percent
forced vital capacity (%FVC) would provide more valuable insights into their influences
on survival and exercise capacity. Additionally, we acknowledge that ILD patients are a
heterogeneous group, however, our study population included only fibrotic-ILDs which
aimed to limit diagnosis-specific differences among our participants. Furthermore, we did
not use a cohort of healthy individuals for comparison with our sample. However, the
nature of calculating z-scores innately compares our sample to healthy population norms
of FFMI, body-fat mass index (BFMI), PhA and IR. Lastly, it would be remiss to not
acknowledge that BIA provides estimations of body composition using prediction
equations as discussed in Chapter 2 Section 2.2.2.1.3; therefore, our results are limited
due to the use of estimates of fat-free mass and body-fat mass rather than actual
measurements. However, in a clinical setting, BIA is the most cost-efficient and practical
application. Although, this research was limited by sample size and, therefore, we could
not preform subgroup statistical analyses, there is reason to believe that individuals with
ILD would benefit from nutrition intervention and support.

Future Research Recommendations and Plans
Continued research is needed to better understand the complex needs of patients with
ILD. There are many research areas that can be further explored within the ILD
population; however, we have identified the most notable research gaps warranting
further exploration. Continued nutrition-related research is needed to increase study
samples size in order to thoroughly explore the risk of malnutrition with specific
medication use and between ILD subtypes, as well as to further explore the influence of
sarcopenic obesity on survival. This may be achieved by a multi-site research study.
There is a notable gap in the research regarding nutrition interventions in ILD, despite
mention in clinical practice guidelines and pulmonary rehabilitation best practice
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guidelines. First, monitoring of nutrition status and body composition longitudinally is
needed to better understand how they relate to clinical parameters such as lung function,
exercise capacity, and survival. Second, research should explore the impact of nutrition
interventions, for example, to improve or preserve muscle mass and explore its relation to
survival, exercise capacity and/or quality of life of patients with ILD. Lastly, within these
future directions, there is great possibility for interprofessional collaboration. For
example, collaboration with physiotherapists would be important to examine the potential
synergistic effect between nutrition interventions and physiotherapy as part of pulmonary
rehabilitation aimed at increasing muscle mass and exercise capacity, and thus improving
patient outcomes.
This research was part of a larger overall study which collected dietary intake
information, biochemical data such as calcium and vitamin D serum levels and functional
data such as hand-grip strength. Data analysis is planned to assess adequacy of intake in
our sample population. This will allow for exploration into the relationship between
protein intake and body composition, and vitamin D intake and serum blood levels in
ILD patients. As well, the relationship between hand-grip strength, a quick and easy
measure of functional capacity, and nutrition status and body composition will be
explored. The results of this planned research may help lay the foundation for further
interventional research.
As this research was limited by its use of bioelectrical impedance analysis to determine
estimated, rather than measured, body composition parameters, we are currently
completing a research study on the use of chest computed topography (CT) scans to
measure body composition parameters using a gold standard method. This research
project aims to determine the prevalence of sarcopenia, or low muscle mass, and
sarcopenic obesity using computed tomography scans in ILD patients both at diagnosis
and through disease progression and which will be used to assess for survival risk. As
well, fat-free mass and body fat mass measured using computed tomography imaging, in
select cases, will be correlated with predictions of body composition assessed using BIA
in order to determine ILD-specific derived BIA regression equations. See Appendix E
for additional information on this project.
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Conclusion
In conclusion, in our sample of 78 fibrotic ILD patients, decreased z-FFMI which was
controlled for age and sex, and SGA-C (severe malnutrition) were significantly
associated with exercise capacity in fibrotic ILD patients independent of lung function.
SPhA was not significantly different between SGA groups, however, z-IR, which
measures cell health, was significantly greater in the SGA-C (severe malnutrition) versus
SGA-A (well-nourished) group indicating worsened cell health in severe malnutrition. zFFMI and severe malnutrition independent of disease severity were significant predictors
of survival in ILD patients. Continued research should focus on nutrition assessment,
intervention and monitoring as this will result in improved understanding of the complex
nutritional concerns of ILD patients. Better understanding these complex needs and
involving nutrition professionals such as RDs in the standard care of ILD patients can
help ensure that ILD patients are provided with the appropriate supports to best manage
their disease.
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NUTRITIONAL STATUS OF PATIENTS WITH INTERSTITIAL LUNG
DISEASE: A CROSS SECTIONAL STUDY
LETTER OF INFORMATION
Introduction
My name is Dr. Janet Madill and I am a Professor in the Foods and Nutrition Department at
Brescia University College. I am currently conducting research into the nutritional status of
patients with interstitial lung disease and would like to invite you to participate in this
study. I am working with Dr. Marco Mura, your respirologist. The purpose of this
information letter is to provide you with enough information for you to decide if you would
like to participate in the study.
Purpose of the study
The purpose of this study is to assess the nutritional status of patients with interstitial lung
disease (ILD), as there is currently little to no information available for patients with ILD.
ILD is a disease process whereby the lungs become inflamed and scarred. The aim of the
study is to measure body composition and nutritional status as this relates to disease and
to determine the appropriate nutrition care plan for patients with interstitial lung disease.
If you agree to participate
If you agree to participate in this study, during your clinic visit, we will review with you
what you have eaten in the last 24-hours. We will provide you with a 3-day food record
sheet, for you to take home and explain to you how to fill in the sheets. We will also ask you
if you would prefer, we call you at the end of each of the 3-days to record what you have
eating, or you may fill in the 3-day food record on your own. As well, we will record your
height and weight. Your body composition, or the amount of muscle, fat and fluid in your
body, will be measured using a BodyStat Analyzer. This will involve resting comfortably on
a bed in the clinic and breathing normally. We will attach 2 electrodes each to the surface of
your foot and hand and record for 2-3 minutes. The BodyStat Analyzer is a non-invasive
device, which measures the impedance value of the body providing quick and effective
analysis of body composition. This is a painless process and it works by passing a safe
battery generated signal through the body and measuring the impedance at a fixed
frequency. We will measure the thickness of your quadriceps femoris muscle in your thigh
using a portable ultrasound machine. This will require you to lay flat on a clinic bed during
the measurement and will require you to expose the skin of your mid though so we can
access to the skin surface. Ultrasound gel and probe will be placed directly on skin surface
using light pressure to produce an ultrasound image used to measure the thickness of your
muscle. Lastly, we will measure your hand-grip strength. This will require you to sit upright
in a chair, and using each hand, squeeze a dynamometer machine as hard as you can. This
Version date: 08/10/2017
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will be repeated three times for accuracy. All testing will be completed during your normal
clinic visit and no additional visits will be required. You may need to stay an additional
thirty to sixty minutes to complete this study. In some cases, if you are not able to make it
to clinic, you may be approached for a visit to take place in the community where members
of the study team will visit you at home to complete the above mentioned data collection. In
this case, we will need to collect your address and postal code solely for travel purposes.
Your address and postal code will not be used for data analysis.
Confidentiality
The information collected will be used for research purposes only, and neither your name
nor information which could identify you will be used in any publication or presentation of
the study results. We will look in your patient records from the hospital including your
personal health information and we will collect only the information we need for this study.
With your consent, we will be contacting your primary physician to obtain any existing
blood work test results on file. All information collected for the study will be kept
confidential. All consent forms will be kept in a locked cabinet file owned by Dr. Marco
Mura at Victoria Hospital in London, ON. Study data will be destroyed after 5 years.
Risks & Benefits
There are no foreseen risks to participating in this study. The only inconvenience
experienced will be that will be meeting with a dietitian to discuss your weight history, and
to talk about what you have eaten in the last 24 hours and to ask you to record what you
eat for 3 days. We will review with you how to complete this and will provide you with the
forms to use to record your food intake. The benefit to the participant is that their future
nutrition care interventions may be better directed.
Voluntary Participation
Participation in this study is voluntary. You may refuse to participate, refuse to answer any
questions, complete any portion of the study or withdraw from the study at any time with
no effect on your medical care. Should you choose not to participate any information about
your study results will not be used.
You will not be compensated for your time should you choose to participate.
Questions
If you have any questions about the conduct of this study or your rights as a research
participant you may contact the Office of Research Ethics, Western University at 519-6613036 or ethics@uwo.ca. If you have any questions about this study, please contact the
principal investigator, Dr. Janet Madill, RD, 1285 Western Road, Brescia University College,
London N6G 1H2, 519-432-8353 extension 28240, jmadill@uwo.ca, or the research
associate, Sylvia Rinaldi, at srinaldi@uwo.ca/sylvia.rinaldi@lhsc.on.ca.
This letter is yours to keep for future reference.
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Participant Initials: ____

NUTRITIONAL STATUS OF PATIENTS WITH INTERSTITIAL LUNG
DISEASE: A CROSS-SECTIONAL STUDY
Dr. Janet Madill, Professor of Foods and Nutrition
Brescia University College
CONSENT FORM
I have read the Letter of Information, have had the nature of the study
explained to me and I agree to participate. All questions have been
answered to my satisfaction.

Name (please print):
Signature:

Date:

Name of Person Obtaining Informed Consent:

Signature of Person Obtaining Informed Consent:
Date:
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Participant Initials: ____

Appendix B: Study Data Collection Forms

Study #:___________

Date:_____________

Appetite

WEIGHT

BMI
Weight Δ

↑ ↓
Intentional/Unintentional

6 months
2 weeks

NUTRITION RELATED

UBW

Good / Fair / Poor
Duration

Nausea
Vomiting
Diarrhea
Constipation

Chewing

Goal
Swallowing

Medications:

IPAQ

Vitamin/Mineral Supplements:

Herbal Supplements:

Vigorous
Activity

Days

Moderate
Activity

Days

Walking for
at least 10
minutes

Days

Laying
down/sitting

Days

Time Spent

Tim e Spent

Time Spent

Time Spent

MEDICAL HISTORY

Diagnosis:
□ Diabetes: Type 1/Type 2
Insulin: Y/N Oral meds: Y/N Neuropathy:
_________
□ CVD: HTN / ↑cholesterol / ↑TG / stroke / MI
□ Liver Disease
□ Renal Disease
□ Gastroesophageal reflux disease/Hiatal Hernia
□ Skin Breakdown/Wound Healing: Location: ________________________
□ Cancer: _________________
□ Surgical Procedures:
Other:

Occupation:
Smoking
Hx
(from pulmonary
function test
sheet)

Pack years:

Labs (Date: _______________)
Calcium
Vitamin D

Version date: 08/16/2016

Years Quit:

3D-FIR given: mail / email / fax / call x 2 weeks

Researcher initials: ______________

Study #:___________

Date:_____________

SGA Score

Subjective Global Assessment Scoring Sheet
PART 1: MEDICAL HISTORY
1. WEIGHT CHANGE
A. Overall change in past 6 months: ___________________ kg / lb

A

B

C

B. Percent change: ______ gain - <5% loss
______ 5 – 10% loss
______ >10% loss
C. Change in past 2 weeks: ______ increase
______ no change; normal weight
______ no change; below usual weight
______ decrease
2. DIETARY INTAKE
______ no change, adequate
______ no change, inadequate
______ change (duration________________)
Current intake: ______ suboptimal or ______ full fluid
______ hypocaloric liquid or ______ starvation
______ Intake borderline; increasing
______ Intake borderline; decreasing
______ Intake poor; no change
______ Intake poor; increasing
______ Intake poor; decreasing
3. GASTROINTESTINAL SYMPTOMS (persisting for > 2 weeks)
Frequency: _________ nausea; _________ vomiting;
_________ diarrhea; _________ constipation;
_________ anorexia; _________ chewing/swallowing issues
______ None
______ Some (daily > 2weeks)
______ All (daily > 2weeks)
4. FUNCTIONAL IMPAIRMENT (nutritionally related)
A. Overall impairment: ______ none
______ moderate (difficulty ambulating/ ADLs)
______ severe (bed/chair-ridden)
B. Change in past 2 weeks: ______ improved
______ no change
______ regressed+
C.
PART 2: PHYSICAL EXAMINATION
Evidence of: Loss of subcutaneous fat
Muscle wasting
Edema
Ascites
PART 3: SGA RATING (check one)
Well-Nourished:
Mildy-Moderately Malnourished:
□A

□A-

Version date: 08/16/2016

□B+

□B

□B-

Severely
Malnourished:
□C+
□C-

Researcher initials: ______________

Study # : ________________

Date: ______________

BodyStat Output (Test # __________)
If possible, the electrodes should be placed on the right side of the body.
Electrodes have been placed on: □ RIGHT □ LEFT
Indicate the logistical circumstances for electrodes be placed on the left side:
______________________________________________________________
(Note: Electrode placement should be on the SAME SIDE of the body as was used for the first
measurement for subsequent measurements)

Presence of pacemaker or metal in body: □ YES □ NO
Is the patient lying flat? □ YES □ NO
If supine position is not possible, indicate the position when measurement is being taken
_______________________
(Note: If supine position is not possible, head of bed should be elevated to 30 degrees)
Treat results with caution? □ YES □ NO

Measure

Value

Height (cm)
Weight (kg)
Age
%
Body Fat
kg
Lean body mass (kg)
Total (kg)
Dry
%
Body Water
L
Extracellular water
Intracellular water
Basal Metabolic Rate
kcal/kg
BMI
BFMI
FFMI
Wellness Marker
Impedance

5 kHz

50 kHz

Resistance
Reactance
Phase Angle

Version date: 08/10/2017

Researcher initials: ____________________

Study # : ________________

Date: ______________

Quadricep Muscle Layer Thickness Ultrasound Output
(Researcher initials: __________)
Length (cm)
Right

QMLT at Min Pressure (cm)

Left

Right

ASIS to top of
patella

Mid-point

Midpoint distance
from top of patella

2/3 point

1/3 distance from
top of patella

Mean

Left

Handgrip Strength
Dominant hand: □ RIGHT □ LEFT Other Considerations:_________________________
Left Hand

Right Hand

Test 1

Test 1

Test 2

Test 2

Test 3

Test 3

Mean

Mean

Pop. mean +/- SD

Pop. mean +/- SD

FiO2

SaO2
(rest)

6-Min Walk Test (Date:______________)
SaO2
Predicted
Borg
Distance (m)
(exercise)
(m)
(rest)

Borg
(exercise)

Pulmonary function tests (Date:________________)
Predicted

Actual

% Predicted

FEV1
DLCO
FVC
Checklist:
□ Vitamin D and calcium requisition
□SGA
□ PFTs
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□ 24-hr Recall
□ 3D-FIR given to participant
(call x 2 weeks / email / mail / fax)
□ Medication and Supplement list

Researcher initials: ____________________
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Bioelectrical Impedance Analysis Protocol
Adapted from the Body Composition Procedures Manual
(National Health Nutrition and Examination Survery 2000)
This dissertation research used the BodyStat® 1500MDD device which estimates body
composition using multifrequency bioelectrical impedance analysis.

Figure 5 BodyStat ® 1500MD device

Protocol
Body Position
Position participant in a supine position (lying flat) with legs separated and arms away
from the trunk of the body (See Figure 6). If the participant is unable to keep their arms
and legs adequately separated, a towel can be placed between the legs or between the arm
and the trunk to ensure separation through the test.

Legs separated
Arms not
touching the body
Figure 6 Proper body position
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Electrode Placement
Two electrode pads are placed on each of the right hand and foot (Figure 7). Clean the
surface of the hand and foot with an alcohol swap before placement of the electrode pads.
Right Hand: Place one pad on the surface of the top of the hand just before the knuckles.
Place the second electrode sticker on the surface of the wrist along the midline of the
ulnar bone (prominent bone on the outer side of the wrist).
Right Foot: Place one pad on the surface of the top of the foot just before the knuckles of
the toes. Place the second electrode sticker on the surface of the ankle along the midline
of the lateral malleoli (prominent bone on the outer side of the ankle).
Connect electrode leads (cords) to the BodyStat® device. Connect the black electrode
lead to the electrode pad on the wrist/ankle using the alligator clip and connect the red
electrode lead to the electrode pads closest to the fingers/toes using the alligator clip.

electrode
pads

electrode
lead

Figure 7 Electrode placement on right hand and foot (BodyStat 2017).
Data Input
Input the participants sex, age, height and weight into the device. Once the participant is
in correct position and electrodes are properly set up, the test can be run. This should take
approximately 5 seconds. Test results will appear on the screen. The test is complete and
the electrodes and leads may be removed from the participant.
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Appendix E: Research Project Proposal Abstract
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Computed Tomography Scan Study Proposal

Interstitial lung disease (ILD) is a group of disorders that involve irritation and swelling
of the tissue lining the lungs. Patients with ILD make up 26-44% of those that receive a
lung transplant in Canada. A component of lung candidacy is patient body mass index,
and often patients are required to lose weight in order to be listed for lung transplant.
However, there is little information known about nutritional concerns of this patient
population through disease progression or leading up to potential lung transplant. Thus,
better understanding nutritional issues has the potential to impact patients’ long-term
outcomes. This study aims to address the question, is the amount of muscle mass at
diagnosis and through disease progression an outcome indicator in ILD? The primary
objective is to determine the prevalence of sarcopenia, or low muscle mass, and
sarcopenic obesity in patients with ILD at diagnosis and through disease progression. The
secondary objective is to examine if sarcopenia and sarcopenic obesity are associated
with survival time. The tertiary objective is to determine if body fat and lean muscle
mass measured by computed tomography imaging, in select cases, is correlated with
measures of body composition assessed using BIA. The research team will review patient
files from a previous pilot study. Previously completed CT-scans will be used to measure
the amount of skeletal mass at various stages of ILD beginning at diagnosis. In select
cases, muscle mass determined using CT-scans will be used to validate previously
completed body composition measures via bioelectrical impedance analysis from the
pilot study. This research addresses a large research potential regarding computed
tomography imaging within the ILD/IPF patient population in the literature. As minimal
information is known about the nutritional status of ILD patients, new and novel research
is needed to understand this vulnerable patient population. It is hoped that the knowledge
gained from the study will help health professionals proactively provide best nutrition
care to their patients beginning at diagnosis.

This research is funded by the Ontario Respiratory Care Society Research grant.
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Appendix F: Ethics Approval
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*Included above is the initial ethics approval notice, however, since this was obtained,
multiple amendments applications have been made and approved to increase sample size,
add new assessment techniques (not included in this research), and to extend study
length.
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Research Timeline
September Commencement of study
2013

•

Ethics approval was received from The University of
Western Ontario Research Ethics Board for Health Sciences
Research Involving Human Subjects (HSREB) on
September 25th, 2013.

October 2013 Recruitment of subjects and data collection

May 2016 Additional study parameters added
•
•

hand-grip strength
quadricep muscle layer thickness via ultrasound technology

January 2019 Data analysis
•
•

Participants recruited up until January 2017 (to allow for 2year survival time) used in data analysis
Recruitment on-going related to hand-grip strength and
quadricep muscle layer thickness data collection

Data Collected
During clinic visit
Bioelectrical impedance analysis*
•
Subjective global assessment*
•
•
24-hr recall
•
Handgrip strength and quadricep muscle layer thickness (added May 2016)
Outside of clinic visit
• 3-day food intake record (obtained by phone, e-mail, mail or fax)
Review of patient charts
• Height*
• Weight*
• Age*
• Specific diagnosis*
• Time from diagnosis*
• Pulmonary function tests*
• 6-min walk distance*
• Medications*
• Comorbidities
*included in this dissertation’s research
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